WO2023230433A1 - Procédés et compositions pour la régulation des alcaloïdes dans le domaine du tabac - Google Patents
Procédés et compositions pour la régulation des alcaloïdes dans le domaine du tabac Download PDFInfo
- Publication number
- WO2023230433A1 WO2023230433A1 PCT/US2023/067281 US2023067281W WO2023230433A1 WO 2023230433 A1 WO2023230433 A1 WO 2023230433A1 US 2023067281 W US2023067281 W US 2023067281W WO 2023230433 A1 WO2023230433 A1 WO 2023230433A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid sequence
- nucleic acid
- tobacco
- tobacco plant
- seq
- Prior art date
Links
- 235000002637 Nicotiana tabacum Nutrition 0.000 title claims abstract description 1151
- 229930013930 alkaloid Natural products 0.000 title claims abstract description 192
- 238000000034 method Methods 0.000 title claims abstract description 83
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 241000208125 Nicotiana Species 0.000 title claims abstract description 51
- 230000001105 regulatory effect Effects 0.000 title description 6
- 244000061176 Nicotiana tabacum Species 0.000 claims abstract description 1102
- 230000014509 gene expression Effects 0.000 claims abstract description 205
- 150000003797 alkaloid derivatives Chemical class 0.000 claims abstract description 177
- 150000007523 nucleic acids Chemical group 0.000 claims description 701
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 523
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 241
- 230000035772 mutation Effects 0.000 claims description 239
- 230000009467 reduction Effects 0.000 claims description 185
- 230000002829 reductive effect Effects 0.000 claims description 163
- 108091032955 Bacterial small RNA Proteins 0.000 claims description 161
- 229920001184 polypeptide Polymers 0.000 claims description 153
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 153
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 153
- 108090000623 proteins and genes Proteins 0.000 claims description 139
- 108020004511 Recombinant DNA Proteins 0.000 claims description 126
- 102000039446 nucleic acids Human genes 0.000 claims description 123
- 108020004707 nucleic acids Proteins 0.000 claims description 123
- 230000027455 binding Effects 0.000 claims description 102
- 239000000463 material Substances 0.000 claims description 96
- 239000002773 nucleotide Substances 0.000 claims description 86
- 125000003729 nucleotide group Chemical group 0.000 claims description 86
- 230000000295 complement effect Effects 0.000 claims description 80
- 235000019505 tobacco product Nutrition 0.000 claims description 76
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 69
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 68
- 229960002715 nicotine Drugs 0.000 claims description 68
- MTXSIJUGVMTTMU-JTQLQIEISA-N (S)-anabasine Chemical compound N1CCCC[C@H]1C1=CC=CN=C1 MTXSIJUGVMTTMU-JTQLQIEISA-N 0.000 claims description 56
- 229930014345 anabasine Natural products 0.000 claims description 56
- SOPPBXUYQGUQHE-JTQLQIEISA-N Anatabine Chemical compound C1C=CCN[C@@H]1C1=CC=CN=C1 SOPPBXUYQGUQHE-JTQLQIEISA-N 0.000 claims description 45
- SOPPBXUYQGUQHE-UHFFFAOYSA-N Anatabine Natural products C1C=CCNC1C1=CC=CN=C1 SOPPBXUYQGUQHE-UHFFFAOYSA-N 0.000 claims description 45
- 239000002679 microRNA Substances 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 44
- MYKUKUCHPMASKF-VIFPVBQESA-N (S)-nornicotine Chemical compound C1CCN[C@@H]1C1=CC=CN=C1 MYKUKUCHPMASKF-VIFPVBQESA-N 0.000 claims description 43
- MYKUKUCHPMASKF-UHFFFAOYSA-N Nornicotine Natural products C1CCNC1C1=CC=CN=C1 MYKUKUCHPMASKF-UHFFFAOYSA-N 0.000 claims description 43
- 230000000694 effects Effects 0.000 claims description 38
- 235000019504 cigarettes Nutrition 0.000 claims description 31
- 108700011259 MicroRNAs Proteins 0.000 claims description 30
- 230000001055 chewing effect Effects 0.000 claims description 24
- 230000001939 inductive effect Effects 0.000 claims description 22
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 235000019506 cigar Nutrition 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 108020004459 Small interfering RNA Proteins 0.000 claims description 9
- 239000004055 small Interfering RNA Substances 0.000 claims description 9
- 108020004485 Nonsense Codon Proteins 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 5
- 231100000221 frame shift mutation induction Toxicity 0.000 claims description 4
- 230000037433 frameshift Effects 0.000 claims description 4
- 230000037434 nonsense mutation Effects 0.000 claims description 4
- 230000037436 splice-site mutation Effects 0.000 claims description 4
- 241000701489 Cauliflower mosaic virus Species 0.000 claims description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 3
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 3
- 108091023045 Untranslated Region Proteins 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 102000007469 Actins Human genes 0.000 claims description 2
- 108010085238 Actins Proteins 0.000 claims description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims description 2
- 108090000848 Ubiquitin Proteins 0.000 claims description 2
- 102000044159 Ubiquitin Human genes 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 abstract description 157
- 108090000489 Carboxy-Lyases Proteins 0.000 abstract description 24
- 210000001519 tissue Anatomy 0.000 description 51
- 108700019146 Transgenes Proteins 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 42
- 235000018102 proteins Nutrition 0.000 description 41
- 230000004048 modification Effects 0.000 description 32
- 238000012986 modification Methods 0.000 description 32
- 102000040430 polynucleotide Human genes 0.000 description 31
- 108091033319 polynucleotide Proteins 0.000 description 31
- 239000002157 polynucleotide Substances 0.000 description 31
- 229920002477 rna polymer Polymers 0.000 description 28
- 238000012239 gene modification Methods 0.000 description 27
- 230000005017 genetic modification Effects 0.000 description 27
- 235000013617 genetically modified food Nutrition 0.000 description 27
- 102100032252 Antizyme inhibitor 2 Human genes 0.000 description 26
- 101000798222 Homo sapiens Antizyme inhibitor 2 Proteins 0.000 description 26
- 229920000768 polyamine Polymers 0.000 description 25
- 238000004519 manufacturing process Methods 0.000 description 22
- 230000008685 targeting Effects 0.000 description 21
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 20
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 20
- 230000009261 transgenic effect Effects 0.000 description 20
- 102000004031 Carboxy-Lyases Human genes 0.000 description 19
- 108700028369 Alleles Proteins 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 16
- 101710163270 Nuclease Proteins 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 14
- 230000000670 limiting effect Effects 0.000 description 14
- 108091070501 miRNA Proteins 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 13
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 12
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 12
- 108091033409 CRISPR Proteins 0.000 description 11
- 108091023040 Transcription factor Proteins 0.000 description 11
- 102000040945 Transcription factor Human genes 0.000 description 11
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 11
- 239000002243 precursor Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 102000053602 DNA Human genes 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 239000005700 Putrescine Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 238000010354 CRISPR gene editing Methods 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 229930002875 chlorophyll Natural products 0.000 description 8
- 235000019804 chlorophyll Nutrition 0.000 description 8
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 8
- 238000001723 curing Methods 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241000238631 Hexapoda Species 0.000 description 7
- 108091022910 Putrescine N-methyltransferase Proteins 0.000 description 7
- 210000001339 epidermal cell Anatomy 0.000 description 7
- 210000000473 mesophyll cell Anatomy 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 108010007784 Methionine adenosyltransferase Proteins 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- 102100030830 Nicotinate-nucleotide pyrophosphorylase [carboxylating] Human genes 0.000 description 6
- 108010086950 Phosphoribosylanthranilate isomerase Proteins 0.000 description 6
- 102100026115 S-adenosylmethionine synthase isoform type-1 Human genes 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- -1 alkaloid compound Chemical class 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 108090000277 nicotinate-nucleotide diphosphorylase (carboxylating) Proteins 0.000 description 6
- 229940063673 spermidine Drugs 0.000 description 6
- 229940063675 spermine Drugs 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- XYMGZPOSIAWOSD-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;pyridine Chemical compound C1=CC=NC=C1.CN1CCCC1C1=CC=CN=C1 XYMGZPOSIAWOSD-UHFFFAOYSA-N 0.000 description 5
- JISYYLCBKJNNEQ-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;pyrrolidine Chemical compound C1CCNC1.CN1CCCC1C1=CC=CN=C1 JISYYLCBKJNNEQ-UHFFFAOYSA-N 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 102000004316 Oxidoreductases Human genes 0.000 description 5
- 108090000854 Oxidoreductases Proteins 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 108020005345 3' Untranslated Regions Proteins 0.000 description 4
- 108020003589 5' Untranslated Regions Proteins 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 4
- 102000016893 Amine Oxidase (Copper-Containing) Human genes 0.000 description 4
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108020005004 Guide RNA Proteins 0.000 description 4
- RMIVMBYMDISYFZ-UHFFFAOYSA-N N-methylputrescine Chemical compound CNCCCCN RMIVMBYMDISYFZ-UHFFFAOYSA-N 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 239000002962 chemical mutagen Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000006114 decarboxylation reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- JOUIQRNQJGXQDC-ZYUZMQFOSA-L nicotinate D-ribonucleotide(2-) Chemical compound O1[C@H](COP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1[N+]1=CC=CC(C([O-])=O)=C1 JOUIQRNQJGXQDC-ZYUZMQFOSA-L 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000000123 paper Substances 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 230000033458 reproduction Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108700024157 Agmatine deiminases Proteins 0.000 description 3
- 241000589158 Agrobacterium Species 0.000 description 3
- 101100010917 Arabidopsis thaliana ERF115 gene Proteins 0.000 description 3
- 102000004452 Arginase Human genes 0.000 description 3
- 108700024123 Arginases Proteins 0.000 description 3
- 101100459261 Cyprinus carpio mycb gene Proteins 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 101150065635 MYC2 gene Proteins 0.000 description 3
- 108090000301 Membrane transport proteins Proteins 0.000 description 3
- 102000003939 Membrane transport proteins Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000006746 NADH Dehydrogenase Human genes 0.000 description 3
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 3
- 101100179449 Nicotiana tabacum A622 gene Proteins 0.000 description 3
- 101100117599 Oryza sativa subsp. japonica DREB1I gene Proteins 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- 101100239644 Xenopus laevis myc-b gene Proteins 0.000 description 3
- 230000009418 agronomic effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- 238000002869 basic local alignment search tool Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 238000002887 multiple sequence alignment Methods 0.000 description 3
- GWWNCLHJCFNTJA-UHFFFAOYSA-N nicandrenone-2 Natural products C12OC2C2(O)CC=CC(=O)C2(C)C(CCC23C)C1C3CCC2(O)C(C)C1OC(O)C2(C)OC2(C)C1 GWWNCLHJCFNTJA-UHFFFAOYSA-N 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- PPOLBRYFPXVWHY-UHFFFAOYSA-N 3,6-Dihydronicotinic acid Chemical compound OC(=O)C1C=CCN=C1 PPOLBRYFPXVWHY-UHFFFAOYSA-N 0.000 description 2
- 102000005758 Adenosylmethionine decarboxylase Human genes 0.000 description 2
- 108010070753 Adenosylmethionine decarboxylase Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101100010908 Arabidopsis thaliana ERF104 gene Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001515826 Cassava vein mosaic virus Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101150094177 Erf gene Proteins 0.000 description 2
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- RYFOJXFXERAMLS-UHFFFAOYSA-N Nicotyrine Chemical compound CN1C=CC=C1C1=CC=CN=C1 RYFOJXFXERAMLS-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 238000003559 RNA-seq method Methods 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 238000001030 gas--liquid chromatography Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 238000012006 liquid chromatography with tandem mass spectrometry Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- DPNGWXJMIILTBS-UHFFFAOYSA-N myosmine Chemical compound C1CCN=C1C1=CC=CN=C1 DPNGWXJMIILTBS-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000037039 plant physiology Effects 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 108091007428 primary miRNA Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 108010059053 quinolinic acid synthetase Proteins 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000000551 statistical hypothesis test Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- YHXKVHQFWVYXIC-JTQLQIEISA-N (S)-nicotine 1-N-oxide Chemical compound CN1CCC[C@H]1C1=CC=C[N+]([O-])=C1 YHXKVHQFWVYXIC-JTQLQIEISA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- VEKIYFGCEAJDDT-UHFFFAOYSA-N 2-pyridin-3-ylpyridine Chemical group N1=CC=CC=C1C1=CC=CN=C1 VEKIYFGCEAJDDT-UHFFFAOYSA-N 0.000 description 1
- WHAIHNKQZOMXJJ-NSHDSACASA-N 3-[(2s)-1-methylpiperidin-2-yl]pyridine Chemical compound CN1CCCC[C@H]1C1=CC=CN=C1 WHAIHNKQZOMXJJ-NSHDSACASA-N 0.000 description 1
- 101150041132 AO gene Proteins 0.000 description 1
- 108020005098 Anticodon Proteins 0.000 description 1
- 101100010913 Arabidopsis thaliana ERF110 gene Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 241000255990 Helicoverpa Species 0.000 description 1
- 241000256257 Heliothis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108091030146 MiRBase Proteins 0.000 description 1
- WHAIHNKQZOMXJJ-UHFFFAOYSA-N N-Methylanabasine Natural products CN1CCCCC1C1=CC=CN=C1 WHAIHNKQZOMXJJ-UHFFFAOYSA-N 0.000 description 1
- ATWWUVUOWMJMTM-UHFFFAOYSA-N N-Methylanatabine Natural products CN1CC=CCC1C1=CC=CN=C1 ATWWUVUOWMJMTM-UHFFFAOYSA-N 0.000 description 1
- 101710167853 N-methyltransferase Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 241000250377 Nicotiana amplexicaulis Species 0.000 description 1
- 241000207746 Nicotiana benthamiana Species 0.000 description 1
- 241000208113 Nicotiana debneyi Species 0.000 description 1
- 241000862464 Nicotiana excelsior Species 0.000 description 1
- 241001495644 Nicotiana glutinosa Species 0.000 description 1
- 241001144503 Nicotiana goodspeedii Species 0.000 description 1
- 241000250366 Nicotiana gossei Species 0.000 description 1
- 241000250368 Nicotiana knightiana Species 0.000 description 1
- 241001144499 Nicotiana maritima Species 0.000 description 1
- 241000250031 Nicotiana megalosiphon Species 0.000 description 1
- 241000228665 Nicotiana nudicaulis Species 0.000 description 1
- 241001144493 Nicotiana obtusifolia Species 0.000 description 1
- 241001144504 Nicotiana occidentalis subsp. hesperis Species 0.000 description 1
- 241000876839 Nicotiana paniculata Species 0.000 description 1
- 241000208133 Nicotiana plumbaginifolia Species 0.000 description 1
- 241000493375 Nicotiana quadrivalvis Species 0.000 description 1
- 241001290303 Nicotiana repanda Species 0.000 description 1
- 241000208134 Nicotiana rustica Species 0.000 description 1
- 241001144480 Nicotiana suaveolens Species 0.000 description 1
- 241000208136 Nicotiana sylvestris Species 0.000 description 1
- 241000579280 Nicotiana tomentosa Species 0.000 description 1
- 241000208138 Nicotiana tomentosiformis Species 0.000 description 1
- 101150100692 ODC gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- YXLXNENXOJSQEI-UHFFFAOYSA-L Oxine-copper Chemical compound [Cu+2].C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1 YXLXNENXOJSQEI-UHFFFAOYSA-L 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101150076721 STIG1 gene Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 101150006589 adc gene Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000011681 asexual reproduction Effects 0.000 description 1
- 238000013465 asexual reproduction Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229950006073 cotinine Drugs 0.000 description 1
- TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 description 1
- QPJDMGCKMHUXFD-UHFFFAOYSA-N cyanogen chloride Chemical compound ClC#N QPJDMGCKMHUXFD-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003571 electronic cigarette Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000000769 gas chromatography-flame ionisation detection Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 108091007426 microRNA precursor Proteins 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000002888 pairwise sequence alignment Methods 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 125000001474 phenylpropanoid group Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000010152 pollination Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- SGDIDUFQYHRMPR-UHFFFAOYSA-N pseudooxynicotine Chemical compound CNCCCC(=O)C1=CC=CN=C1 SGDIDUFQYHRMPR-UHFFFAOYSA-N 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
Definitions
- this disclosure provides a method for producing a modified tobacco plant comprising: (a) crossing at least one tobacco plant of a first tobacco variety with at least one tobacco plant of a second tobacco variety to produce at least one progeny tobacco seed, where the at least one tobacco plant of the first tobacco variety comprises a recombinant DNA construct, where the recombinant DNA construct comprises a heterologous promoter operably linked to a nucleic acid sequence encoding at least one small RNA molecule capable of binding to and reducing the expression of at least one endogenous nucleic acid sequence encoding a polypeptide at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18, where the recombinant DNA construct is not present in the endogenous nucleic acid sequence in a control tobacco plant of the same variety; and (b) selecting for at least one progeny tobacco seed, or a plant germinated therefrom, where the at least one tobacco seed or plant germinated therefrom comprises the
- Any tobacco plant, or part thereof, provided herein is specifically envisioned for use with any method provided herein.
- any modified tobacco plant, or part thereof, is specifically envisioned for use with any method provided herein.
- Any nucleic acid sequence, amino acid sequence, or other composition provided herein is specifically envisioned for use with any method provided herein.
- Tobacco plants typically produce alkaloids at levels between 2% and 4% of their total dry weight. Nicotine is a major alkaloid compound in tobacco plants, and it often accounts for approximately 95% of the total alkaloid content of the plants. The remaining pool of alkaloids primarily comprises other structurally-related alkaloids such as anabasine, anatabine, and nornicotine.
- this disclosure provides a modified tobacco plant, or part thereof, comprising at least one non-natural mutation in at least four different endogenous nucleic acid sequences selected from the group consisting of SEQ ID NOs: 1-6. In another aspect, this disclosure provides a modified tobacco plant, or part thereof, comprising at least one non-natural mutation in at least five different endogenous nucleic acid sequences selected from the group consisting of SEQ ID NOs: 1-6. In another aspect, this disclosure provides a modified tobacco plant, or part thereof, comprising at least one non-natural mutation in each of SEQ ID NOs: 1-6.
- this disclosure provides a modified tobacco plant, or part thereof, comprising at least one non-natural mutation in each of a first endogenous nucleic acid sequence and a second endogenous nucleic acid sequence, where the first endogenous nucleic acid sequence is at least 90% identical to SEQ ID NO: 2, and where the second endogenous nucleic acid sequence is at least 90% identical to SEQ ID NO: 3.
- this disclosure provides a modified tobacco plant, or part thereof, comprising at least one non-natural mutation in an endogenous nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7-12.
- this disclosure provides a modified tobacco plant, or part thereof, comprising at least one non-natural mutation in at least two different endogenous nucleic acid sequences selected from the group consisting of SEQ ID NOs: 7-12.
- this disclosure provides a modified tobacco plant, or part thereof, comprising at least one non-natural mutation in at least three different endogenous nucleic acid sequences selected from the group consisting of SEQ ID NOs: 7-12.
- this disclosure provides a modified tobacco plant, or part thereof, comprising at least one non-natural mutation in at least four endogenous nucleic acid sequences, where the at least four endogenous nucleic acid sequences encode different polypeptides comprising an amino acid sequence at least 95% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- this disclosure provides a modified tobacco plant, or part thereof, comprising at least one non-natural mutation in at least five endogenous nucleic acid sequences, where the at least five endogenous nucleic acid sequences encode different polypeptides comprising an amino acid sequence at least 95% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- this disclosure provides a modified tobacco plant, or part thereof, comprising at least one non-natural mutation in an endogenous nucleic acid sequence at least 95% identical to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 7-12.
- this disclosure provides a modified tobacco plant, or part thereof, comprising at least one non-natural mutation in an endogenous nucleic acid sequence, where the endogenous nucleic acid sequence encodes a polypeptide comprising an amino acid sequence at least 99% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- this disclosure provides a modified tobacco plant, or part thereof, comprising at least one non-natural mutation in an endogenous nucleic acid sequence at least 99% identical to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6.
- this disclosure provides a modified tobacco plant, or part thereof, comprising at least one non-natural mutation in an endogenous nucleic acid sequence at least 99% identical to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 7-12.
- this disclosure provides a modified tobacco plant, or part thereof, comprising at least one non-natural mutation in an endogenous nucleic acid sequence, wherein the endogenous nucleic acid sequence encodes a polypeptide comprising an amino acid sequence at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18, wherein the modified tobacco plant comprises at least one non-natural mutation in a first endogenous nucleic acid sequence, and at least one non-natural mutation in a second endogenous nucleic acid sequence, wherein the first endogenous nucleic acid sequence encodes a polypeptide comprising an amino acid sequence at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18, wherein the second endogenous nucleic acid sequence encodes a polypeptide comprising an amino acid sequence at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18, and wherein the first and second end
- this disclosure provides a modified tobacco plant, or part thereof, comprising a recombinant DNA construct comprising a heterologous promoter operably linked to a nucleic acid encoding at least one small RNA molecule capable of binding to and reducing the expression of at least one endogenous nucleic acid sequence at least 90% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-6.
- this disclosure provides a modified tobacco plant, or part thereof, comprising a recombinant DNA construct comprising a heterologous promoter operably linked to a nucleic acid encoding at least one small RNA molecule capable of binding to and reducing the expression of at least one endogenous nucleic acid sequence at least 90% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7-12.
- this disclosure provides a modified tobacco plant, or part thereof, comprising a recombinant DNA construct comprising a heterologous promoter operably linked to a nucleic acid encoding at least one small RNA molecule capable of binding to and reducing the expression of at least one endogenous nucleic acid sequence at least 95% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7-12.
- this disclosure provides a modified tobacco plant, or part thereof, comprising a recombinant DNA construct comprising a heterologous promoter operably linked to a nucleic acid encoding at least one small RNA molecule capable of binding to and reducing the expression of a first endogenous nucleic acid sequence encoding a polypeptide at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18 and a second endogenous nucleic acid sequence encoding a polypeptide at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18, and where the first and second endogenous nucleic acid sequences are not identical to each other.
- this disclosure provides a modified tobacco plant, or part thereof, comprising a recombinant DNA construct comprising a heterologous promoter operably linked to a nucleic acid encoding at least one small RNA molecule capable of binding to and reducing the expression of a first endogenous nucleic acid sequence encoding a polypeptide at least 95% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18 and a second endogenous nucleic acid sequence encoding a polypeptide at least 95% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18, and where the first and second endogenous nucleic acid sequences are not identical to each other.
- this disclosure provides a modified tobacco plant, or part thereof, comprising a recombinant DNA construct comprising a heterologous promoter operably linked to a nucleic acid encoding at least one small RNA molecule capable of binding to and reducing the expression of a first endogenous nucleic acid sequence encoding a polypeptide at least 99% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18 and a second endogenous nucleic acid sequence encoding a polypeptide at least 99% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18, and where the first and second endogenous nucleic acid sequences are not identical to each other.
- this disclosure provides a modified tobacco plant, or part thereof, comprising a recombinant DNA construct comprising a heterologous promoter operably linked to a nucleic acid encoding at least one small RNA molecule capable of binding to and reducing the expression of a first endogenous nucleic acid sequence and a second endogenous nucleic acid sequence, wherein the first and second endogenous nucleic acid sequences are each at least 80% identical to a sequence selected from the group consisting of SEQ ID NOs: 7-12, and where the first and second endogenous nucleic acid sequences are not identical to each other.
- this disclosure provides a modified tobacco plant, or part thereof, comprising a recombinant DNA construct comprising a heterologous promoter operably linked to a nucleic acid encoding at least one small RNA molecule capable of binding to and reducing the expression of a first endogenous nucleic acid sequence and a second endogenous nucleic acid sequence, wherein the first and second endogenous nucleic acid sequences are each at least 99% identical to a sequence selected from the group consisting of SEQ ID NOs: 1-6, and where the first and second endogenous nucleic acid sequences are not identical to each other.
- this disclosure provides a modified tobacco plant, or part thereof, comprising a recombinant DNA construct comprising a heterologous promoter operably linked to a nucleic acid encoding at least one small RNA molecule capable of binding to and reducing the expression of a first endogenous nucleic acid sequence and a second endogenous nucleic acid sequence, where the first endogenous nucleic acid sequence comprises a sequence that is at least 99% identical to SEQ ID NO: 2 and where the second endogenous nucleic acid sequence comprises a sequence that is at least 99% identical to SEQ ID NO: 3.
- this disclosure provides a modified tobacco plant, or part thereof, comprising a recombinant DNA construct comprising a heterologous promoter operably linked to a nucleic acid encoding at least one small RNA molecule capable of binding to and reducing the expression of a first endogenous nucleic acid sequence and a second endogenous nucleic acid sequence, where the first endogenous nucleic acid sequence comprises a sequence that is 100% identical to SEQ ID NO: 2 and where the second endogenous nucleic acid sequence comprises a sequence that is 100% identical to SEQ ID NO: 3.
- this disclosure provides a modified tobacco plant, or part thereof, comprising a recombinant DNA construct comprising a heterologous promoter operably linked to a nucleic acid encoding at least one small RNA molecule capable of binding to and reducing the expression 1 of a first endogenous nucleic acid sequence and a second endogenous nucleic acid sequence, where the first endogenous nucleic acid sequence comprises a sequence that is at least 99% identical to SEQ ID NO: 7 and where the second endogenous nucleic acid sequence comprises a sequence that is at least 99% identical to SEQ ID NO: 12.
- a nucleic acid molecule encoding at least one small RNA molecule comprises a sequence at least 80% identical to one of SEQ ID NOs: 32 and 33. In an aspect, a nucleic acid molecule encoding at least one small RNA molecule comprises a sequence at least 85% identical to one of SEQ ID NOs: 32 and 33. In an aspect, a nucleic acid molecule encoding at least one small RNA molecule comprises a sequence at least 90% identical to one of SEQ ID NOs: 32 and 33. In an aspect, a nucleic acid molecule encoding at least one small RNA molecule comprises a sequence at least 95% identical to one of SEQ ID NOs: 32 and 33.
- this disclosure provides a modified tobacco plant, or part thereof, comprising a recombinant DNA construct comprising a heterologous promoter operably linked to a nucleic acid sequence at least 80% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7-12.
- this disclosure provides a modified tobacco plant, or part thereof, comprising at least one non-natural mutation in an endogenous nucleic acid sequence that modulates the expression or activity of a gene, where the gene encodes a polypeptide comprising an amino acid sequence at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- this disclosure provides a modified tobacco plant, or part thereof, comprising at least one non-natural mutation in an endogenous nucleic acid sequence that modulates the expression or activity of a gene, where the gene encodes an RNA sequence at least 80% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7-12.
- this disclosure provides a modified tobacco plant, or part thereof, comprising (a) a genetic modification in a gene; or (b) a genetic modification targeting the gene; where the genetic modification downregulates the expression or activity of the gene, where the gene encodes an amino acid sequence having at least 80% identity or similarity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- this disclosure provides a modified tobacco plant, or part thereof, comprising (a) a genetic modification in a gene; or (b) a genetic modification targeting the gene; where the genetic modification downregulates the expression or activity of the gene, where the gene encodes a nucleic acid sequence having at least 80% identity to a polynucleotide sequence selected from the group consisting of SEQ ID NOs: 7-12.
- modified in the context of a plant, refers to a plant comprising a genetic alteration introduced for certain purposes and beyond natural polymorphisms.
- a modified plant can comprise a non-natural mutation or a recombinant DNA construct.
- a modified tobacco plant comprises a non-natural mutation.
- a modified tobacco plant comprises a recombinant DNA construct.
- a modified tobacco plant comprises a genetic modification.
- a “mutation” refers to an inheritable genetic modification introduced into a gene to alter the expression or activity of a product encoded by a reference sequence of the gene.
- a tobacco plant, or part thereof is homozygous for at least one non- natural mutation. In another aspect, a tobacco plant, or part thereof, is heterozygous for at least one non-natural mutation. In another aspect, a tobacco plant, or part thereof, is homozygous for an introduced recombinant DNA construct. In another aspect, a tobacco plant, or part thereof, is hemizygous for an introduced recombinant DNA construction. In a further aspect, a tobacco plant, or part thereof, is heterozygous for an introduced recombinant DNA construct.
- a dominant negative allele abrogates or reduces the normal function of an allele in a heterozygous or homozygous state.
- Dominant positive alleles can increase normal gene function (e.g., a hypermorph) or provide new functions for a gene (e.g., a neomorph).
- a semi-dominant allele occurs when penetrance of a linked phenotype in individuals heterozygous for the allele is less than that which is observed in individuals homozygous for the allele.
- a mutation provided herein creates a dominant negative allele of the mutated locus. In another aspect, a mutation provided herein creates a dominant positive allele of a mutated locus.
- inducing a mutation comprises the use of a chemical mutagen.
- a chemical mutagen comprises ethyl methanesulfonate (EMS).
- inducing a mutation comprises the use of a transposon. In another aspect, inducing a mutation comprises the use of Agrobacterium. [0076] In a further aspect, inducing a mutation comprises the use of a nuclease.
- inducing a mutation comprises the use of a CRISPR/CasX nuclease. In an aspect, inducing a mutation comprises the use of a CRISPR/CasY nuclease. In an aspect, inducing a mutation comprises the use of a Csml nuclease.
- inducing a mutation comprises the use of a base editor.
- a “base editor” refers to a catalytically impaired Cas nuclease fused to a nucleotide deaminase.
- base editors further comprise DNA repair proteins.
- a base editor is a cytosine base editor.
- a cytosine base editor enables C-G to T-A transitions.
- a base editor is an adenine base editor.
- An adenine base editor enables A-T to G-C conversion.
- a base editor is a C-to-G base editor.
- a “substitution” refers to the replacement of one or more nucleotides or amino acids to a given polynucleotide or amino acid sequence, respectively, as compared to an endogenous reference polynucleotide or amino acid sequence.
- a mutation comprises an inversion.
- An “inversion” refers to when a segment of a polynucleotide or amino acid sequence is reversed end- to-end.
- a “duplication” refers to when a segment of a polynucleotide or amino acid sequence is repeated. The repeated segment can immediately follow the original segment, or it can be separated from the original segment by one or more nucleotides or amino acids.
- a mutation provided herein comprises a mutation selected from the group consisting of an insertion, a deletion, a substitution, a duplication, and an inversion.
- a non-natural mutation comprises a mutation selected from the group consisting of a substitution, a deletion, an insertion, a duplication, and an inversion of one or more nucleotides relative to an endogenous nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12.
- a “frameshift mutation” refers to an insertion or deletion to a nucleic acid sequence that shifts the frame for translating the nucleic acid sequence to an amino acid sequence.
- a “splice-site mutation” refers to a mutation in a nucleic acid sequence that causes an intron to be retained for protein translation, or, alternatively, for an exon to be excluded from protein translation. Splice-site mutations can cause nonsense, missense, or frameshift mutations. [0084] Mutations in coding regions of genes (e.g., exonic mutations) can result in a truncated protein or polypeptide when a mutated messenger RNA (mRNA) is translated into a protein or polypeptide.
- mRNA messenger RNA
- a premature stop codon refers to a nucleotide triplet within an mRNA transcript that signals a termination of protein translation.
- a “premature stop codon” refers to a stop codon positioned earlier (e.g., on the 5 ’-side) than the normal stop codon position in an endogenous mRNA transcript.
- several stop codons are known in the art, including “UAG,” “UAA,” “UGA,” “TAG,” “TAA,” and “TGA.”
- a non-natural mutation comprises a mutation in a sequence region selected from the group consisting of a promoter, a 5'-UTR, a 3'- UTR, an exon, an intron, and a terminator.
- an “endogenous” nucleic acid sequence refers to a nucleic acid sequence that occurs naturally in the genome of an organism. Endogenous nucleic acid sequences do not include heterologous sequences inserted into a genome via deliberate human intervention. Similarly, endogenous amino acid sequences are sequences that exist naturally via translation of an endogenous nucleic acid molecule. In an aspect, a nucleic acid sequence provided herein is an endogenous nucleic acid sequence.
- heterologous refers to a sequence (nucleic acid or amino acid) that originates from a foreign species, or, if from the same species, is substantially modified from its native form in composition and/or genomic locus by deliberate human intervention.
- the term also is applicable to nucleic acid constructs, also referred to herein as “polynucleotide constructs” or “nucleotide constructs.”
- a “heterologous” nucleic acid construct is intended to mean a construct that originates from a foreign species, or, if from the same species, is substantially modified from its native form in composition and/or genomic locus by deliberate human intervention.
- percent identity or “percent identical” as used herein in reference to two or more nucleotide or amino acid sequences is calculated by (i) comparing two optimally aligned sequences (nucleotide or amino acid) over a window of comparison (the “alignable” region or regions), (ii) determining the number of positions at which the identical nucleic acid base (for nucleotide sequences) or amino acid residue (for proteins and polypeptides) occurs in both sequences to yield the number of matched positions, (iii) dividing the number of matched positions by the total number of positions in the window of comparison, and then (iv) multiplying this quotient by 100% to yield the percent identity.
- two aliphatic (e.g., glycine, alanine, valine, leucine, isoleucine) amino acid residues can be substituted for each other in a conservative substitution;
- two hydroxyl (e.g., serine, cysteine, threonine, methionine) amino acid residues can be substituted for each other in a conservative substitution;
- two aromatic (e.g., phenylalanine, tyrosine, tryptophan) amino acid residues can be substituted for each other in a conservative substitution;
- two basic (e.g., histidine, lysine, arginine) amino acid residues can be substituted for each other in a conservative substitution; and
- two acid (e.g., aspartate, glutamate, asparagine, glutamine) amino acid residues can be substituted for each other in a conservative substitution.
- the alignment and percent identity between two sequences can be as determined by the ClustalW algorithm, see, e.g., Chenna etal., “Multiple sequence alignment with the Clustal series of programs,” Nucleic Acids Research 31: 3497-3500 (2003); Thompson et al., “Clustal W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice,” Nucleic Acids Research 22: 4673-4680 (1994); Larkin MA et al., “Clustal W and Clustal X version 2.0,” Bioinformatics 23: 2947-48 (2007); and Altschul etal. "Basic local alignment search tool.” J. Mol. Biol. 215:403-410 (1990), the entire contents and disclosures of which are incorporated herein by reference.
- the “percent complementarity” can be calculated by (i) optimally base-pairing or hybridizing the two nucleotide sequences in a linear and fully extended arrangement (i.e., without folding or secondary structures) over a window of comparison, (ii) determining the number of positions that base-pair between the two sequences over the window of comparison to yield the number of complementary positions, (iii) dividing the number of complementary positions by the total number of positions in the window of comparison, and (iv) multiplying this quotient by 100% to yield the percent complementarity of the two sequences.
- Optimal base pairing of two sequences can be determined based on the known pairings of nucleotide bases, such as G- C, A-T, and A-U, through hydrogen binding.
- polynucleotide or “nucleic acid molecule” is not intended to limit the present disclosure to polynucleotides comprising deoxyribonucleic acid (DNA).
- RNA ribonucleic acid
- polynucleotides and nucleic acid molecules can comprise ribonucleotides and combinations of ribonucleotides and deoxyribonucleotides.
- deoxyribonucleotides and ribonucleotides include both naturally occurring molecules and synthetic analogues.
- a “recombinant nucleic acid” refers to a nucleic acid molecule formed by laboratory methods of genetic recombination, such as, without being limiting, molecular cloning.
- a “recombinant DNA construct” refers to a DNA molecule formed by laboratory methods of genetic recombination.
- Polypeptides can be purified from natural sources (e.g., a biological sample) by known methods such as DEAE ion exchange, gel filtration, and hydroxyapatite chromatography.
- a polypeptide also can be purified, for example, by expressing a nucleic acid in an expression vector.
- a purified polypeptide can be obtained by chemical synthesis. The extent of purity of a polypeptide can be measured using any appropriate method, e.g, column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
- a nucleic acid sequence provided herein is at least 70% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12 and 19- 30. In another aspect, a nucleic acid sequence provided herein is at least 75% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12 and 19- 30. In another aspect, a nucleic acid sequence provided herein is at least 80% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12 and 19- 30. In another aspect, a nucleic acid sequence provided herein is at least 85% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12 and 19- 30.
- a nucleic acid sequence provided herein is at least 88% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12 and 19- 30. In another aspect, a nucleic acid sequence provided herein is at least 90% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12 and 19- 30. In another aspect, a nucleic acid sequence provided herein is at least 91% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12 and 19- 30. In another aspect, a nucleic acid sequence provided herein is at least 92% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12 and 19- 30.
- a nucleic acid sequence provided herein is at least 93% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12 and 19- 30. In another aspect, a nucleic acid sequence provided herein is at least 94% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12 and 19- 30. In another aspect, a nucleic acid sequence provided herein is at least 95% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12 and 19- 30. In another aspect, a nucleic acid sequence provided herein is at least 96% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12 and 19- 30.
- a nucleic acid sequence provided herein is at least 97% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12 and 19- 30. In another aspect, a nucleic acid sequence provided herein is at least 98% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12 and 19- 30. In another aspect, a nucleic acid sequence provided herein is at least 99% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12 and 19- 30. In another aspect, a nucleic acid sequence provided herein is 100% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12 and 19-30.
- an endogenous nucleic acid sequence provided herein is at least 70% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In another aspect, an endogenous nucleic acid sequence provided herein is at least 75% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In another aspect, an endogenous nucleic acid sequence provided herein is at least 80% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In another aspect, an endogenous nucleic acid sequence provided herein is at least 85% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In another aspect, an endogenous nucleic acid sequence provided herein is at least 88% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to
- an endogenous nucleic acid sequence provided herein is at least 90% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In another aspect, an endogenous nucleic acid sequence provided herein is at least 91% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In another aspect, an endogenous nucleic acid sequence provided herein is at least 92% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In another aspect, an endogenous nucleic acid sequence provided herein is at least 93% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12.
- an endogenous nucleic acid sequence provided herein is at least 98% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In another aspect, an endogenous nucleic acid sequence provided herein is at least 99% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In another aspect, an endogenous nucleic acid sequence provided herein is 100% identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12.
- Detection can be accomplished using detectable labels.
- label is intended to encompass the use of direct labels as well as indirect labels.
- Detectable labels include enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
- an amino acid sequence provided herein is at least 70% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In another aspect, an amino acid sequence provided herein is at least 75% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In another aspect, an amino acid sequence provided herein is at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In another aspect, an amino acid sequence provided herein is at least 85% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- an amino acid sequence provided herein is at least 93% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In another aspect, an amino acid sequence provided herein is at least 94% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In another aspect, an amino acid sequence provided herein is at least 95% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In another aspect, an amino acid sequence provided herein is at least 96% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- an amino acid sequence provided herein is at least 97% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In another aspect, an amino acid sequence provided herein is at least 98% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In another aspect, an amino acid sequence provided herein is at least 99% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In another aspect, an amino acid sequence provided herein is 100% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- a nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 70% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, a nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 75% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, a nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- a nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 85% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, a nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 88% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, a nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 90% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- a nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 97% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, a nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 98% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, a nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 99% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, a nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence 100% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- an endogenous nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 70% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, an endogenous nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 75% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, an endogenous nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- an endogenous nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 91% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, an endogenous nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 92% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, an endogenous nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 93% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- an endogenous nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 94% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, an endogenous nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 95% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, an endogenous nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 96% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- an endogenous nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 97% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, an endogenous nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 98% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, an endogenous nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence at least 99% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, an endogenous nucleic acid sequence provided herein encodes a polypeptide comprising an amino acid sequence 100% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- promoter refers to a DNA sequence that contains an RNA polymerase binding site, a transcription start site, and/or a TATA box and assists or promotes the transcription and expression of an associated transcribable polynucleotide sequence and/or gene (or transgene).
- a promoter can be synthetically produced, varied, or derived from a known or naturally occurring promoter sequence or other promoter sequence.
- a promoter can also include a chimeric promoter comprising a combination of two or more heterologous sequences.
- a promoter of the present application can thus include variants of promoter sequences that are similar in composition, but not identical to, other promoter sequence(s) known or provided herein.
- a constitutive promoter is selected from the group consisting of a Cauliflower Mosaic Virus 35S promoter, a ubiquitin promoter, an actin promoter, an opine promoter, and an alcohol dehydrogenase promoter.
- Promoters that drive expression during certain periods or stages of development are referred to as “developmental” promoters.
- a root tissue-preferred promoter is a cassava vein mosaic virus (CsVMV) promoter.
- CsVMV cassava vein mosaic virus
- An “inducible” promoter is a promoter that initiates transcription in response to an environmental stimulus such as heat, cold, drought, light, or other stimuli, such as wounding or chemical application.
- this disclosure provides a heterologous promoter. In another aspect, this disclosure provides a promoter that is operably linked to a heterologous polynucleotide. In another aspect, this disclosure provides a polynucleotide sequence that is operably linked to a heterologous promoter.
- operably linked refers to a functional linkage between two or more elements.
- an operable linkage between a polynucleotide of interest and a regulatory sequence is a functional link that allows for expression of the polynucleotide of interest.
- Operably linked elements may be contiguous or non-contiguous.
- a promoter provided herein is operably linked to a heterologous nucleic acid molecule.
- a nucleic acid molecule provided herein is a small RNA molecule.
- a nucleic acid molecule encodes a small RNA molecule.
- a “small RNA molecule” refers to a non-coding RNA molecule of between 16 nucleotides and 50 nucleotides in length. In an aspect, a small RNA molecule comprises between 16 nucleotides and 40 nucleotides. In another aspect, a small RNA molecule comprises between 16 nucleotides and 30 nucleotides. In another aspect, a small RNA molecule comprises between 18 nucleotides and 50 nucleotides. In another aspect, a small RNA molecule comprises between 18 nucleotides and 40 nucleotides. In another aspect, a small RNA molecule comprises between 18 nucleotides and 30 nucleotides.
- a small RNA molecule comprises between 18 nucleotides and 25 nucleotides. In another aspect, a small RNA molecule comprises between 20 nucleotides and 28 nucleotides. In another aspect, a small RNA molecule comprises between 20 nucleotides and 24 nucleotides. In another aspect, a small RNA molecule comprises between 21 nucleotides and 23 nucleotides. In another aspect, a small RNA molecule comprises 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides.
- a small RNA molecule is selected from the group consisting of a double-stranded RNA, a small interfering RNA (siRNA), a /raw.s-acting siRNA, and a microRNA (miRNA).
- this disclosure also provides guide RNAs (gRNAs) and prime editing gRNAs that bind to any one of SEQ ID NOs: 1 to 12.
- miRNAs are generally of between about 19 to about 25 nucleotides (commonly about 20-24 nucleotides in plants), that guide cleavage in trans of target transcripts, negatively regulating the expression of genes involved in various regulation and development pathways. In some cases, miRNAs serve to guide in-phase processing of siRNA primary transcripts.
- a small RNA molecule comprises 100% complementarity with a nucleic acid molecule comprising a sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In an aspect, a small RNA molecule comprises at least 95% complementarity over 21 consecutive nucleotides of a nucleic acid molecule comprising a sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In an aspect, a small RNA molecule comprises at least 90% complementarity over 21 consecutive nucleotides of a nucleic acid molecule comprising a sequence selected from the group consisting of SEQ ID NOs: 1 to 12.
- MIR genes have been reported to occur in intergenic regions, both isolated and in clusters in the genome, but can also be located entirely or partially within introns of other genes (both protein-coding and non-protein-coding). For a review of miRNA biogenesis, see Kim (2005) Nature Rev. Mol. Cell. Biol., 6:376-385. Transcription of MIR genes can be, at least in some cases, under promotional control of a MIR gene's own promoter.
- the primary transcript termed a “pri- miRNA” can be quite large (several kilobases) and can be polycistronic, containing one or more pre-miRNAs (fold-back structures containing a stem-loop arrangement that is processed to the mature miRNA) as well as the usual 5' "cap” and polyadenylated tail of an mRNA.
- Maturation of a mature miRNA from its corresponding precursors differs significantly between animals and plants.
- pri-miRNAs and pre-miRNAs are believed to be largely processed to the mature miRNA entirely in the nucleus
- the pri-miRNA transcript is processed in the nucleus by the animal-specific enzyme Drosha, followed by export of the pre-miRNA to the cytoplasm where it is further processed to the mature miRNA.
- Mature miRNAs in plants are typically 21 nucleotides in length.
- Transgenic expression of miRNAs can be employed to regulate expression of the miRNA's target gene or genes. Inclusion of a miRNA recognition site in a transgenically expressed transcript is also useful in regulating expression of the transcript. Recognition sites of miRNAs have been validated in all regions of an mRNA, including the 5' untranslated region, coding region, and 3' untranslated region, indicating that the position of the miRNA target site relative to the coding sequence may not necessarily affect suppression. Because miRNAs are important regulatory elements in eukaryotes, transgenic suppression of miRNAs is useful for manipulating biological pathways and responses.
- promoters of MIR genes can have very specific expression patterns (e.g., cellspecific, tissue-specific, temporally specific, or inducible), and thus are useful in recombinant constructs to induce such specific transcription of a DNA sequence to which they are operably linked.
- miRNAs their precursors, their recognition sites, and their promoters are described in detail in U.S. Patent Application Publication 2006/0200878 Al, incorporated by reference herein.
- Non-limiting examples of these utilities include: (1) the expression of a native miRNA or miRNA precursor sequence to suppress a target gene; (2) the expression of an artificial miRNA or miRNA precursor sequence to suppress a target gene; (3) expression of a transgene with a miRNA recognition site, where the transgene is suppressed when the mature miRNA is expressed; (4) expression of a transgene driven by a miRNA promoter.
- Designing an artificial miRNA sequence can be as simple as substituting sequence that is complementary to the intended target for nucleotides in the miRNA stem region of the miRNA precursor, as demonstrated by Zeng et al. (2002) Mol. Cell, 9:1327-1333.
- One nonlimiting example of a general method for determining nucleotide changes in the native miRNA sequence to produce the engineered miRNA precursor includes the following steps: (a) Selecting a unique target sequence of at least 18 nucleotides specific to the target gene, e.g., by using sequence alignment tools such as BLAST (see, for example, Altschul et al. (1990) J. Mol. Biol., 215:403-410; Altschul et al.
- 19-mers are selected that have all or most of the following characteristics: (1) a Reynolds score>4, (2) a GC content between about 40% to about 60%, (3) a negative AAG, (4) a terminal adenosine, (5) lack of a consecutive run of 4 or more of the same nucleotide; (6) a location near the 3' terminus of the target gene; (7) minimal differences from the miRNA precursor transcript.
- the additional nucleotide at position 20 is preferably matched to the selected target sequence, and the nucleotide at position 21 is preferably chosen to either be unpaired to prevent spreading of silencing on the target transcript or paired to the target sequence to promote spreading of silencing on the target transcript; and (d) transforming the artificial miRNA into a plant.
- RNAi knockdown of a candidate gene e.g., via the use of an artificial miRNA or an siRNA
- a mutation e.g., missense or nonsense mutations
- an RNAi knockdown of a candidate gene can both cause reduction of expression and/or decreased protein activity and can cause identical or similar phenotypes in plants. See, for example, Agrawal et al., Microbiology and Molecular Biology Reviews, 67:657-685 (2003).
- a small RNA provided herein comprises at nucleic acid sequence at least 75% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In an aspect, a small RNA provided herein comprises at nucleic acid sequence at least 80% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In an aspect, a small RNA provided herein comprises at nucleic acid sequence at least 85% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12.
- a small RNA provided herein comprises at nucleic acid sequence at least 90% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In an aspect, a small RNA provided herein comprises at nucleic acid sequence at least 95% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In an aspect, a small RNA provided herein comprises at nucleic acid sequence at least 96% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12.
- a small RNA provided herein comprises at nucleic acid sequence at least 97% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In an aspect, a small RNA provided herein comprises at nucleic acid sequence at least 98% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In an aspect, a small RNA provided herein comprises at nucleic acid sequence at least 99% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In an aspect, a small RNA provided herein comprises at nucleic acid sequence 100% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12.
- a small RNA provided herein comprises at nucleic acid sequence at least 90% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7-12. In an aspect, a small RNA provided herein comprises at nucleic acid sequence at least 95% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7-12. In an aspect, a small RNA provided herein comprises at nucleic acid sequence at least 96% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7-12.
- a small RNA provided herein comprises at nucleic acid sequence at least 97% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7-12. In an aspect, a small RNA provided herein comprises at nucleic acid sequence at least 98% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7- 12. In an aspect, a small RNA provided herein comprises at nucleic acid sequence at least 99% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7-12. In an aspect, a small RNA provided herein comprises at nucleic acid sequence 100% identical or complementary to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7-12.
- a small RNA provided herein comprises a nucleic acid sequence at least 88.7% identical or complementary to at least 18 contiguous nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12.
- a small RNA provided herein comprises a nucleic acid sequence at least 94.3% identical or complementary to at least 18 contiguous nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12.
- a small RNA provided herein comprises a nucleic acid sequence 100% identical or complementary to at least 18 contiguous nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In another aspect, a small RNA provided herein comprises a nucleic acid sequence at least 85% identical or complementary to at least 20 contiguous nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In another aspect, a small RNA provided herein comprises a nucleic acid sequence at least 90% identical or complementary to at least 20 contiguous nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12.
- a small RNA provided herein comprises a nucleic acid sequence at least 95% identical or complementary to at least 20 contiguous nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12. In another aspect, a small RNA provided herein comprises a nucleic acid sequence 100% identical or complementary to at least 20 contiguous nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12.
- a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence encoding a polypeptide at least 70% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence encoding a polypeptide at least 75% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence encoding a polypeptide at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence encoding a polypeptide at least 85% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence encoding a polypeptide at least 91% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence encoding a polypeptide at least 92% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence encoding a polypeptide at least 93% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence encoding a polypeptide at least 94% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence encoding a polypeptide at least 95% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence encoding a polypeptide at least 96% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence encoding a polypeptide at least 97% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. In an aspect, a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence encoding a polypeptide at least 98% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence at least 70% identical to nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12, or an RNA transcribed therefrom. In an aspect, a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence at least 75% identical to nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12, or an RNA transcribed therefrom.
- a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence at least 88% identical to nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12, or an RNA transcribed therefrom. In an aspect, a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence at least 90% identical to nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12, or an RNA transcribed therefrom.
- a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence at least 91% identical to nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12, or an RNA transcribed therefrom. In an aspect, a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence at least 92% identical to nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12, or an RNA transcribed therefrom.
- a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence at least 93% identical to nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12, or an RNA transcribed therefrom. In an aspect, a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence at least 94% identical to nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12, or an RNA transcribed therefrom.
- a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence at least 95% identical to nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12, or an RNA transcribed therefrom. In an aspect, a small RNA molecule provided herein is capable of binding to and reducing the expression of a nucleic acid sequence at least 96% identical to nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12, or an RNA transcribed therefrom.
- a first nucleic acid molecule that is capable of binding to a second nucleic acid molecule binds to the second nucleic acid molecule.
- a first nucleic acid molecule can “hybridize” a second nucleic acid molecule via non-covalent interactions (e.g., Watson-Crick base-pairing) in a sequence-specific, antiparallel manner (i.e., a nucleic acid specifically binds to a complementary nucleic acid) under the appropriate in vitro and/or in vivo conditions of temperature and solution ionic strength.
- standard Watson-Crick basepairing includes: adenine pairing with thymine, adenine pairing with uracil, and guanine (G) pairing with cytosine (C) [DNA, RNA],
- G guanine
- C cytosine
- G/U base-pairing is partially responsible for the degeneracy (i.e., redundancy) of the genetic code in the context of tRNA anti-codon base-pairing with codons in mRNA.
- a guanine of a protein-binding segment (dsRNA duplex) of a subject DNA-targ eting RNA molecule is considered complementary to an uracil, and vice versa.
- dsRNA duplex protein-binding segment of a subject DNA- targeting RNA molecule
- the position is not considered to be non- complementary, but is instead considered to be complementary.
- Hybridization requires that the two nucleic acids contain complementary sequences, although mismatches between bases are possible.
- the conditions appropriate for hybridization between two nucleic acids depend on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of complementation between two nucleotide sequences, the greater the value of the melting temperature (Tm) for hybrids of nucleic acids having those sequences. Lor hybridizations between nucleic acids with short stretches of complementarity (e.g. complementarity over 35 or fewer nucleotides) the position of mismatches becomes important (see Sambrook el al.). Typically, the length for a hybridizable nucleic acid is at least about 10 nucleotides.
- Illustrative minimum lengths for a hybridizable nucleic acid are: at least about 15 nucleotides; at least about 20 nucleotides; at least about 22 nucleotides; at least about 25 nucleotides; and at least about 30 nucleotides). Lurthermore, the skilled artisan will recognize that the temperature and wash solution salt concentration may be adjusted as necessary according to factors such as length of the region of complementation and the degree of complementation.
- sequence of polynucleotide need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable or hybridizable. Moreover, a polynucleotide may hybridize over one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure or hairpin structure).
- an antisense nucleic acid in which 18 of 20 nucleotides of the antisense compound are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity.
- the remaining noncomplementary nucleotides may be clustered or interspersed with complementary nucleotides and need not be contiguous to each other or to complementary nucleotides.
- Percent complementarity between particular stretches of nucleic acid sequences within nucleic acids can be determined routinely using BLAST® programs (basic local alignment search tools) and PowerBLAST programs known in the art (see Altschul etal., J. Mol.
- a small RNA molecule reduces the expression of any nucleic acid sequence to which it is capable of binding.
- a non-natural mutation provided herein reduces the expression of the mutated nucleic acid sequence as compared to the non-mutated nucleic acid sequence in a control plant grown under comparable conditions.
- Reduced expression of an endogenous nucleic acid sequence can be measured using any suitable method known in the art.
- Non-limiting examples of measuring expression include quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), RNA blot (e.g., a Northern blot), RNA sequencing. Differences in expression can be described as an absolute quantification or a relative quantification. See, for example, Livak and Schmittgen, Methods, 25:402-408 (2001). If an endogenous nucleic acid sequence encodes a protein, changes in expression can be inferred by examining the accumulation of the encoded protein.
- Non-limiting examples of measuring protein accumulation include Western blots and enzyme-linked immunosorbent assays (ELISAs).
- a reduction in expression is measured using qRT-PCR. In another aspect, a reduction in expression is measured using an RNA blot. In another aspect, a reduction in expression is measured using RNA sequencing. In a further aspect, a reduction in expression is measured using a Western blot. In yet a further aspect, a reduction in expression is measured using an ELISA.
- a non-natural mutation in a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12 results in a reduced level of expression of the nucleic acid sequence as compared to the nucleic acid sequence lacking the non-natural mutation in a control plant grown under comparable conditions.
- a non-natural mutation in a nucleic acid sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18 results in a reduced level of expression of the nucleic acid sequence as compared to the nucleic acid sequence lacking the non-natural mutation in a control plant grown under comparable conditions.
- a reduction in expression comprises a reduction of at least 1% as compared to expression in the same tissue of a control plant grown under comparable conditions. In another aspect, a reduction in expression comprises a reduction of at least 5% as compared to expression in the same tissue of a control plant grown under comparable conditions. In another aspect, a reduction in expression comprises a reduction of at least 10% as compared to expression in the same tissue of a control plant grown under comparable conditions. In another aspect, a reduction in expression comprises a reduction of at least 25% as compared to expression in the same tissue of a control plant grown under comparable conditions. In another aspect, a reduction in expression comprises a reduction of at least 50% as compared to expression in the same tissue of a control plant grown under comparable conditions.
- a reduction in expression comprises a reduction of at least 75% as compared to expression in the same tissue of a control plant grown under comparable conditions. In another aspect, a reduction in expression comprises a reduction of at least 90% as compared to expression in the same tissue of a control plant grown under comparable conditions. In another aspect, a reduction in expression comprises a reduction of at least 95% as compared to expression in the same tissue of a control plant grown under comparable conditions.
- a reduction in expression comprises a reduction of between 1% and 25% as compared to expression in the same tissue of a control plant grown under comparable conditions. In another aspect, a reduction in expression comprises a reduction of between 25% and 90% as compared to expression in the same tissue of a control plant grown under comparable conditions. In another aspect, a reduction in expression comprises a reduction of between 50% and 90% as compared to expression in the same tissue of a control plant grown under comparable conditions. In another aspect, a reduction in expression comprises a reduction of between 25% and 75% as compared to expression in the same tissue of a control plant grown under comparable conditions. [00144] In an aspect, a reduction in expression comprises a statistically significant reduction as compared to expression in the same tissue of a control plant grown under comparable conditions.
- a non-natural mutation results in a reduced level of activity by a protein or polypeptide encoded by a nucleic acid sequence provided herein as compared to the activity of a control plant grown under comparable conditions.
- a non-natural mutation in an endogenous nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12 reduces the level of activity by a protein or polypeptide encoded by the nucleic acid sequence as compared to activity of a protein or polypeptide encoded by the endogenous nucleic acid sequence in a control tobacco plant when grown under comparable conditions, where the nucleic acid sequence lacks the non-natural mutation in the control tobacco plant.
- a non-natural mutation in an endogenous nucleic acid sequence where the endogenous nucleic acid sequence encodes an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18 reduces the level of activity by a protein or polypeptide encoded by the nucleic acid sequence as compared to activity of a protein or polypeptide encoded by the endogenous nucleic acid sequence in a control tobacco plant when grown under comparable conditions, where the nucleic acid sequence lacks the non-natural mutation in the control tobacco plant.
- activity refers to the ability to carry out an enzymatic function.
- activity of a decarboxylase protein or polypeptide refers to the ability of a decarboxylase to remove a carboxyl group from an organic molecule substrate.
- the mutated decarboxylase may be able to (a) remove a carboxyl group from an organic molecule substrate at an increased rate as compared to a nonmutated decarboxylase protein; (b) be able to remove carboxyl groups from substrates that are not suitable substrates for a non-mutated decarboxylase; or (c) both (a) and (b).
- the activity of decarboxylases can be measured using techniques standard in the art. For example, see Yu el al., Seely and Pegg, J. Biol. Chem., 258:2496-2500
- a non-natural mutation results in increased expression of a nucleic acid sequence.
- a non-natural mutation results in an increased level of expression of said nucleic acid sequence as compared to expression of said nucleic acid sequence in the same tissue of a control tobacco plant when grown under comparable conditions, wherein said nucleic acid sequence lacks the at least one non-natural mutation in said control tobacco plant.
- an increased level of expression comprises an increase of at least 5% as compared to expression in the same tissue of a control plant grown under comparable conditions. In another aspect, an increased level of expression comprises an increase of at least 10% as compared to expression in the same tissue of a control plant grown under comparable conditions. In another aspect, an increased level of expression comprises an increase of at least 25% as compared to expression in the same tissue of a control plant grown under comparable conditions. In another aspect, an increased level of expression comprises an increase of at least 50% as compared to expression in the same tissue of a control plant grown under comparable conditions. In another aspect, an increased level of expression comprises an increase of at least 75% as compared to expression in the same tissue of a control plant grown under comparable conditions.
- an increased level of expression comprises an increase of at least 100% as compared to expression in the same tissue of a control plant grown under comparable conditions. In another aspect, an increased level of expression comprises an increase of at least 200% as compared to expression in the same tissue of a control plant grown under comparable conditions. In another aspect, an increased level of expression comprises an increase of at least 500% as compared to expression in the same tissue of a control plant grown under comparable conditions.
- a non-natural mutation results in an increased level of activity by a protein or polypeptide encoded by said nucleic acid sequence as compared to activity of a protein or polypeptide encoded by said nucleic acid sequence in a control tobacco plant when grown under comparable conditions, wherein said nucleic acid sequence lacks the at least one non-natural mutation in said control tobacco plant.
- Nicotine is the primary natural alkaloid in commercialized cigarette tobacco, and it accounts for approximately 90% of the alkaloid content in Nicotiana tabacum.
- other major alkaloids in tobacco include cotinine, nornicotine, myosmine, nicotyrine, anabasine and anatabine.
- minor tobacco alkaloids include nicotine-n- oxide, N-methyl anatabine, N-methyl anabasine, pseudooxynicotine, 2,3 dipyridyl and others.
- an alkaloid is selected from the group consisting of anabasine, anatabine, nicotine, and nornicotine.
- Alkaloid levels can be assayed by methods known in the art, for example by quantification based on gas-liquid chromatography, high performance liquid chromatography, radio-immunoassays, enzyme-linked immunosorbent assays, and mass spectrometry.
- nicotinic alkaloid levels can be measured by a GC-FID method based on CORESTA Recommended Method No. 7, 1987 and ISO Standards (ISO TC 126N 394 E. See also Hibi et al., Plant Physiology 100: 826-35 (1992) for a method using gas-liquid chromatography equipped with a capillary column and an FID detector.
- Alkaloid levels can be assayed from any plant tissue. Non-limiting examples include leaf and hairy root cultures. Additionally, alkaloid levels can be assayed in cured plant materials or in plant materials that have not been cured.
- tobacco total alkaloids can be measured using a segmented-flow colorimetric method developed for analysis of tobacco samples as adapted by Skalar Instrument Co. (West Chester, PA) and described by Collins et al., Tobacco Science 13:79-81 (1969).
- samples of tobacco are dried, ground, and extracted prior to analysis of total alkaloids and reducing sugars.
- the method then employs an acetic acid/methanol/water extraction and charcoal for decolorization. Determination of total alkaloids was based on the reaction of cyanogen chloride with nicotine alkaloids in the presence of an aromatic amine to form a colored complex which is measured at 460 nm.
- the level of an individual alkaloid is measured based on a freeze-dried cured leaf sample using liquid chromatography with tandem mass spectrometry (LC/MS/MS). In an aspect, the level of an individual alkaloid is measured based on a freeze-dried hairy root culture sample using liquid chromatography with tandem mass spectrometry (LC/MS/MS).
- the nicotine or alkaloid level (or another leaf chemistry or property characterization) of a tobacco plant is measured after topping in a pooled leaf sample collected from leaf number 3, 4, and 5 after topping.
- leaves from the same or comparable stalk position(s) and developmental stage(s) are intended so that the comparison can demonstrate effects due to genotype differences, not from other factors.
- leaf 3 of a control plant is intended as a reference point for comparing with leaf 3 of a modified plant comprising a non-natural mutation or recombinant DNA construct.
- “topping” refers to the removal of the stalk apex, including the shoot apical meristem, flowers, and up to several adjacent leaves, when a tobacco plant is near vegetative maturity and around the start of reproductive growth.
- tobacco plants are topped in the button stage (soon after the flower begins to appear).
- greenhouse or field-grown tobacco plants can be topped when 50% of the plants have at least one open flower. Topping a tobacco plant results in the loss of apical dominance and also induce increased alkaloid production.
- the alkaloid level (or another leaf chemistry or property characterization; e.g., polyamines) of a tobacco plant is measured about 2 weeks after topping. Other time points can also be used.
- alkaloid level (or another leaf chemistry or property characterization) of a tobacco plant is measured about 1 , 2, 3, 4, or 5 weeks after topping.
- the nicotine, alkaloid, or polyamine level (or another leaf chemistry or property characterization; e.g., polyamines) of a tobacco plant is measured about 3, 5, 7, 10, 12, 14, 17, 19, or 21 days after topping.
- a modified tobacco plant, or part thereof, comprising at least one nonnatural mutation in an endogenous nucleic acid produces at least one leaf comprising a reduced amount of at least one alkaloid as compared to the amount of the alkaloid in a control tobacco plant lacking the at least one non-natural mutation in the endogenous nucleic acid when grown under comparable conditions.
- a modified tobacco plant, or part thereof, comprising a recombinant DNA construct provided herein produces at least one leaf comprising a reduced amount of at least one alkaloid as compared to the amount of the alkaloid in a control tobacco plant lacking the recombinant DNA construct when grown under comparable conditions.
- a reduced level of at least one alkaloid comprises a reduction of at least 0.5% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of at least 1% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of at least 2% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of at least 3% as compared to a control tobacco plant when grown under comparable conditions.
- a reduced level of at least one alkaloid comprises a reduction of at least 4% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of at least 5% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of at least 10% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of at least 15% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of at least 20% as compared to a control tobacco plant when grown under comparable conditions.
- a reduced level of at least one alkaloid comprises a reduction of at least 25% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of at least 35% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of at least 50% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of at least 75% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of at least 90% as compared to a control tobacco plant when grown under comparable conditions.
- a reduced level of at least one alkaloid comprises a reduction of at between 1% and 20% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of at between 1% and 10% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of at between 1% and 5% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of at between 10% and 75% as compared to a control tobacco plant when grown under comparable conditions.
- a reduced level of at least one alkaloid comprises a reduction of nicotine by at least 4% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of nicotine by at least 5% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of nicotine by at least 10% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of nicotine by at least 15% as compared to a control tobacco plant when grown under comparable conditions.
- a modified tobacco plant comprises a nicotine level of less than or equal to 11 mg/g of dry weight. In an aspect, a modified tobacco plant comprises a nicotine level of less than or equal to 10 mg/g of dry weight. In an aspect, a modified tobacco plant comprises a nicotine level of less than or equal to 9 mg/g of dry weight. In an aspect, a modified tobacco plant comprises a nicotine level of less than or equal to 8 mg/g of dry weight. In an aspect, a modified tobacco plant comprises a nicotine level of less than or equal to 7 mg/g of dry weight. In an aspect, a modified tobacco plant comprises a nicotine level of less than or equal to 6 mg/g of dry weight.
- a reduced level of at least one alkaloid comprises a reduction of anatabine by between 1% and 20% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of anatabine by between 1% and 10% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of anatabine by between 1% and 5% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of anatabine by between 10% and 75% as compared to a control tobacco plant when grown under comparable conditions.
- a reduced level of at least one alkaloid comprises a reduction of nornicotine by at least 4% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of nornicotine by at least 5% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of nornicotine by at least 10% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of nornicotine by at least 15% as compared to a control tobacco plant when grown under comparable conditions.
- a reduced level of at least one alkaloid comprises a reduction of nornicotine by at least 20% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of nornicotine by at least 25% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of nornicotine by at least 35% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of nornicotine by at least 50% as compared to a control tobacco plant when grown under comparable conditions.
- a reduced level of at least one alkaloid comprises a reduction of nornicotine by at least 75% as compared to a control tobacco plant when grown under comparable conditions. In an aspect, a reduced level of at least one alkaloid comprises a reduction of nornicotine by at least 90% as compared to a control tobacco plant when grown under comparable conditions.
- Cells, tissues and organs can be from seed, fruit, leaf, cotyledon, hypocotyl, meristem, embryos, endosperm, root, shoot, stem, trichome, pod, flower, inflorescence, stalk, pedicel, style, stigma, receptacle, petal, sepal, pollen, anther, filament, ovary, ovule, pericarp, phloem, vascular tissue.
- this disclosure provides a tobacco plant chloroplast.
- this disclosure provides epidermal cells, stomata cell, leaf or root hairs, a storage root, or a tuber.
- this disclosure provides a tobacco protoplast.
- a “progeny tobacco plant” or “progeny tobacco seed” can be from any filial generation, e.g., Fi, F2, F3, F4, F5, Fe, F7, etc.
- a tobacco plant, or part thereof is of a tobacco variety selected from the group consisting of a flue-cured variety, a bright variety, a Burley variety, a Virginia variety, a Maryland variety, a dark variety, a Galpao variety, an Oriental variety, and a Vietnamese variety.
- a modified tobacco plant, or part thereof, provided herein is of a tobacco variety selected from the group consisting of a flue-cured variety, a bright variety, a Burley variety, a Virginia variety, a Maryland variety, a dark variety, a Galpao variety, an Oriental variety, and a Turkish variety.
- a cured tobacco leaf or plant part is of a tobacco variety selected from the group consisting of a flue cured variety, a bright variety, a Burley variety, a Virginia variety, a Maryland variety, a dark variety, a Galpao variety, an Oriental variety, and a Vietnamese variety. Skilled artisans further understand that cured tobacco does not constitute a living organism and is not capable of growth or reproduction
- Flue-cured tobaccos (also called “Virginia” or “bright” tobaccos) amount to approximately 40% of world tobacco production. Flue-cured tobaccos are often also referred to as “bright tobacco” because of the golden-yellow to deep-orange color it reaches during curing. Flue- cured tobaccos have a light, bright aroma and taste. Flue-cured tobaccos are generally high in sugar and low in oils. Major flue-cured tobacco growing countries are Argentina, Brazil, China, India, Africa and the United States of America.
- tobacco plants or seeds or modified tobacco plants or seeds provided herein are of a flue-cured tobacco variety selected from the group consisting of the varieties listed in Table 2, and any variety essentially derived from any one of the foregoing varieties. See WO 2004/041006 Al.
- modified tobacco plants or seeds provided herein are in a flue-cured variety selected from the group consisting of K326, K346, and NCI 96.
- Air-cured tobaccos include “Burley,” “Maryland,” and “dark” tobaccos.
- the common factor linking air-cured tobaccos is that curing occurs primarily without artificial sources of heat and humidity.
- Burley tobaccos are light to dark brown in color, high in oil, and low in sugar. Burley tobaccos are typically air-cured in barns.
- Major Burley growing countries include Argentina, Brazil, Italy, Malawi, and the United States of America.
- tobacco plants or seeds or modified tobacco plants or seeds provided herein are of a Burley tobacco variety selected from the group consisting of the tobacco varieties listed in Table 3, and any variety essentially derived from any one of the foregoing varieties.
- modified tobacco plants or seeds provided herein are in a Burley variety selected from the group consisting of TN 90, KT 209, KT 206, KT212, and HB 4488.
- tobacco plants or seeds or modified tobacco plants or seeds provided herein are of a Maryland tobacco variety selected from the group consisting of the tobacco varieties listed in Table 4, and any variety essentially derived from any one of the foregoing varieties.
- tobacco plants or seeds or modified tobacco plants or seeds provided herein are of an cigar tobacco variety selected from the group consisting of the tobacco varieties listed in Table 7, and any variety essentially derived from any one of the foregoing varieties.
- a tobacco plant, or part thereof is from a variety selected from the group consisting of the tobacco varieties listed in Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, and Table 8.
- a tobacco plant, or part thereof is from a variety listed in Table 2.
- a tobacco plant, or part thereof is from a variety listed in Table 3.
- a tobacco plant, or part thereof is from a variety listed in Table 4.
- a tobacco plant, or part thereof is from a variety listed in Table 5.
- a tobacco plant, or part thereof is from a variety listed in Table 6.
- a tobacco plant, or part thereof is from a variety listed in Table 7.
- a tobacco plant, or part thereof is from a variety listed in Table 8.
- a modified tobacco plant, or part thereof is from a variety selected from the group consisting of the tobacco varieties listed in Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, and Table 8.
- a modified tobacco plant, or part thereof is from a variety listed in Table 2.
- a modified tobacco plant, or part thereof is from a variety listed in Table 3.
- a modified tobacco plant, or part thereof is from a variety listed in Table 4.
- a modified tobacco plant, or part thereof is from a variety listed in Table 5.
- a modified tobacco plant, or part thereof is from a variety listed in Table 6.
- a modified tobacco plant, or part thereof is from a variety listed in Table 7.
- a tobacco cell is from a variety selected from the group consisting of the tobacco varieties listed in Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, and Table 8.
- a tobacco cell is from a variety listed in Table 2.
- a tobacco cell is from a variety listed in Table 3.
- a tobacco cell is from a variety listed in Table 4.
- a tobacco cell is from a variety listed in Table 5.
- a tobacco cell is from a variety listed in Table 6.
- a tobacco cell is from a variety listed in Table 7.
- a tobacco cell is from a variety listed in Table 8.
- a tobacco plant or variety provided herein is an inbred tobacco plant or variety.
- an “inbred” tobacco variety is a variety that has been bred for genetic homogeneity.
- a “hybrid” is created by crossing two plants from different varieties or species, such that the progeny comprises genetic material from each parent. Skilled artisans recognize that higher order hybrids can be generated as well. For example, a first hybrid can be made by crossing Variety C with Variety D to create a C x D hybrid, and a second hybrid can be made by crossing Variety E with Variety F to create an E x F hybrid. The first and second hybrids can be further crossed to create the higher order hybrid (C x D) x (E x F) comprising genetic information from all four parent varieties.
- a modified tobacco plant provided herein is a hybrid tobacco plant. In another aspect, a modified tobacco seed provided herein is a hybrid tobacco seed.
- this disclosure provides a method for producing a modified tobacco plant comprising: (a) crossing at least one tobacco plant of a first tobacco variety with at least one tobacco plant of a second tobacco variety to produce at least one progeny tobacco seed, where the at least one tobacco plant of the first tobacco variety comprises a non-natural mutation in an endogenous nucleic acid sequence at least 80% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-6, where the non-natural mutation is not present in the endogenous nucleic acid sequence in a control tobacco plant of the first tobacco variety; and (b) selecting for at least one progeny tobacco seed, or a plant germinated therefrom, wherein the at least one tobacco seed or plant germinated therefrom comprises the non-natural mutation.
- this disclosure provides a method for producing a modified tobacco plant comprising: (a) crossing at least one tobacco plant of a first tobacco variety with at least one tobacco plant of a second tobacco variety to produce at least one progeny tobacco seed, where the at least one tobacco plant of the first tobacco variety comprises a recombinant DNA construct, where the recombinant DNA construct comprises a heterologous promoter operably linked to a nucleic acid sequence encoding at least one small RNA molecule capable of binding to and reducing the expression of at least one endogenous nucleic acid sequence encoding a polypeptide at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18, were the recombinant DNA construct is not present in a control tobacco plant of the first tobacco variety; and (b) selecting for at least one progeny tobacco seed, or a plant germinated therefrom, wherein the at least one progeny tobacco seed or plant germinated therefrom comprises the recombinant
- this disclosure provides a method for producing a modified tobacco plant comprising: (a) crossing at least one tobacco plant of a first tobacco variety with at least one tobacco plant of a second tobacco variety to produce at least one progeny tobacco seed, where the at least one tobacco plant of the first tobacco variety comprises a recombinant DNA construct, where the recombinant DNA construct comprises a heterologous promoter operably linked to a nucleic acid sequence encoding at least one small RNA molecule capable of binding to and reducing the expression of at least one endogenous nucleic acid sequence at least 80% identical or similar to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-6, were the recombinant DNA construct is not present in a control tobacco plant of the first tobacco variety; and (b) selecting for at least one progeny tobacco seed, or a plant germinated therefrom, wherein the at least one progeny tobacco seed or plant germinated therefrom comprises the recombinant DNA construct.
- this disclosure provides a method for producing a modified tobacco plant comprising: (a) crossing at least one tobacco plant of a first tobacco variety with at least one tobacco plant of a second tobacco variety to produce at least one progeny tobacco seed, where the at least one tobacco plant of the first tobacco variety comprises a recombinant DNA construct, where the recombinant DNA construct comprises a heterologous promoter operably linked to a nucleic acid sequence encoding at least one small RNA molecule capable of binding to and reducing the expression of at least one endogenous nucleic acid sequence at least 80% identical or similar to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7-12, were the recombinant DNA construct is not present in a control tobacco plant of the first tobacco variety; and (b) selecting for at least one progeny tobacco seed, or a plant germinated therefrom, where the at least one progeny tobacco seed or plant germinated therefrom comprises the recombinant DNA construct.
- this disclosure provides a method for producing a modified tobacco plant comprising: (a) crossing at least one tobacco plant of a first tobacco variety with at least one tobacco plant of a second tobacco variety to produce at least one progeny tobacco seed, where the at least one tobacco plant of the first tobacco variety comprises a recombinant DNA construct, where the recombinant DNA construct comprises a heterologous promoter operably linked to a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18, where the recombinant DNA construct is not present in a control tobacco plant of the first tobacco variety; and (b) selecting for at least one progeny tobacco seed, or a plant germinated therefrom, where the at least one progeny tobacco seed or plant germinated therefrom comprises the recombinant DNA construct.
- this disclosure provides a method for producing a modified tobacco plant comprising: (a) crossing at least one tobacco plant of a first tobacco variety with at least one tobacco plant of a second tobacco variety to produce at least one progeny tobacco seed, where the at least one tobacco plant of the first tobacco variety comprises a recombinant DNA construct, where the recombinant DNA construct comprises a heterologous promoter operably linked to a nucleic acid sequence at least 80% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-6, where the recombinant DNA construct is not present in a control tobacco plant of the first tobacco variety; and (b) selecting for at least one progeny tobacco seed, or a plant germinated therefrom, where the at least one progeny tobacco seed or plant germinated therefrom comprises the recombinant DNA construct.
- this disclosure provides a method for producing a modified tobacco plant comprising: (a) crossing at least one tobacco plant of a first tobacco variety with at least one tobacco plant of a second tobacco variety to produce at least one progeny tobacco seed, where the at least one tobacco plant of the first tobacco variety comprises a recombinant DNA construct, where the recombinant DNA construct comprises a heterologous promoter operably linked to a nucleic acid sequence at least 80% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7-12, where the recombinant DNA construct is not present in a control tobacco plant of the first tobacco variety; and (b) selecting for at least one progeny tobacco seed, or a plant germinated therefrom, where the at least one progeny tobacco seed or plant germinated therefrom comprises the recombinant DNA construct.
- the first tobacco variety and second tobacco variety are the same tobacco variety.
- the foregoing methods the first tobacco variety and second tobacco variety are the same tobacco variety.
- crossing refers to the deliberate mating of two plants.
- crossing comprises pollination and/or fertilization of a first tobacco plant by a second tobacco plant.
- the two tobacco plants being crossed can be distantly related, closely related, or identical.
- the two tobacco plants being crossed are both modified tobacco plants.
- the two tobacco plants being crossed are of the same tobacco variety.
- the two tobacco plants being crossed are of two different tobacco varieties.
- one of the two tobacco plants being crossed is male sterile.
- one of the two tobacco plants being crossed is female sterile.
- at least one of the two tobacco plants being crossed is a hybrid tobacco plant.
- at least one of the two tobacco plants being crossed is a modified tobacco plant.
- a tobacco plant or variety provided herein is female sterile.
- a modified tobacco plant or variety provided herein is female sterile.
- female sterile plants can be made by mutating the STIG1 gene. See, for example, Goldman et al. 1994, EMBO Journal 13:2976-2984.
- a modified tobacco plant provided herein is female sterile.
- control plant refers to a plant of identical, or nearly identical, genetic makeup as the modified plant being compared, except for the non-natural mutation or recombinant DNA construct provided herein that was introduced to the modified plant.
- a modified tobacco plant described herein is a low-alkaloid variety or low-alkaloid plant.
- LA Burley 21 (LA BU21) is a low-alkaloid variety of tobacco.
- LA BU21 is produced by incorporation of a low alkaloid gene(s) from a Cuban cigar variety into Burley 21 through several backcrosses. It has approximately 0.2% total alkaloids (dry weight) compared to the about 3.5% (dry weight) of its parent, Burley 21.
- LA BU21 has a leaf grade well below commercially acceptable standards.
- the present disclosure provides tobacco plants, or part thereof, comprising a low nicotine or low alkaloid-conferring mutation or transgene (e.g., a genetic modification in or targeting one or more ADC, AO, or ODC) and capable of producing a leaf comprising a comparable level of one or more polyamines relative to a comparable leaf of a control plant not comprising the same mutation or transgene.
- a comparable level of one or more polyamines is within 20%, 17.5%, 15%, 12.5%, 10%, 7.5%, 5%, 2.5%, or 1% of the level in a comparable leaf of a control plant not comprising the same mutation or transgene.
- a comparable level of one or more polyamines is between 0.5% and 1%, between 1% and 2%, between 2% and 3%, between 3% and 4%, between 4% and 5%, between 5% and 6%, between 6% and 7%, between 7% and 8%, between 8% and 9%, between 9% and 10%, between 11% and 12%, between 12% and 13%, between 13% and 14%, between 14% and 15%, between 15% and 16%, between 16% and 17%, between 17% and 18%, between 18% and 19%, or between 19% and 20% of the level in a comparable leaf of a control plant not comprising the same mutation or transgene.
- a comparable level of one or more polyamines is between 0.5% and 5%, between 5% and 10%, or between 10% and 20% of the level in a comparable leaf of a control plant not comprising the same mutation or transgene.
- the present disclosure provides ADC mutant or transgenic tobacco plants or parts thereof, AO mutant or transgenic tobacco plants or parts thereof, or ODC mutant or transgenic tobacco plants or parts thereof, capable of producing a leaf comprising a comparable chlorophyll level relative to a comparable leaf of a control plant not comprising the same mutation or transgene.
- a comparable chlorophyll level is within 20%, 17.5%, 15%, 12.5%, 10%, 7.5%, 5%, 2.5%, or 1% of the level in a comparable leaf of a control plant not comprising the same mutation or transgene.
- the present disclosure provides ADC mutant or transgenic tobacco plants or parts thereof, AO mutant or transgenic tobacco plants or parts thereof, or ODC mutant or transgenic tobacco plants or parts thereof, capable of producing a leaf comprising a comparable number of mesophyll cell per unit of leaf area relative to a comparable leaf of a control plant not comprising the same mutation or transgene.
- a comparable number of mesophyll cell per unit of leaf area is within 20%, 17.5%, 15%, 12.5%, 10%, 7.5%, 5%, 2.5%, or 1% of the level in a comparable leaf of a control plant not comprising the same mutation or transgene.
- a comparable number of mesophyll cell per unit of leaf area is between 0.5% and 1%, between 1% and 2%, between 2% and 3%, between 3% and 4%, between 4% and 5%, between 5% and 6%, between 6% and 7%, between 7% and 8%, between 8% and 9%, between 9% and 10%, between 11% and 12%, between 12% and 13%, between 13% and 14%, between 14% and 15%, between 15% and 16%, between 16% and 17%, between 17% and 18%, between 18% and 19%, or between 19% and 20% of the level in a comparable leaf of a control plant not comprising the same mutation or transgene.
- a comparable number of mesophyll cell per unit of leaf area is between 0.5% and 5%, between 5% and 10%, or between 10% and 20% of the level in a comparable leaf of a control plant not comprising the same mutation or transgene.
- the present disclosure provides ADC mutant or transgenic tobacco plants or parts thereof, AO mutant or transgenic tobacco plants or parts thereof, or ODC mutant or transgenic tobacco plants or parts thereof, capable of producing a leaf comprising a comparable epidermal cell size relative to a comparable leaf of a control plant not comprising the same mutation or transgene.
- a comparable epidermal cell size is within 20%, 17.5%, 15%, 12.5%, 10%, 7.5%, 5%, 2.5%, or 1% of the level in a comparable leaf of a control plant not comprising the same mutation or transgene.
- a comparable epidermal cell size is between 0.5% and 1%, between 1% and 2%, between 2% and 3%, between 3% and 4%, between 4% and 5%, between 5% and 6%, between 6% and 7%, between 7% and 8%, between 8% and 9%, between 9% and 10%, between 11% and 12%, between 12% and 13%, between 13% and 14%, between 14% and 15%, between 15% and 16%, between 16% and 17%, between 17% and 18%, between 18% and 19%, or between 19% and 20% of the level in a comparable leaf of a control plant not comprising the same mutation or transgene.
- a comparable epidermal cell size is between 0.5% and 5%, between 5% and 10%, or between 10% and 20% of the level in a comparable leaf of a control plant not comprising the same mutation or transgene.
- the present disclosure provides ADC mutant or transgenic tobacco plants or parts thereof, AO mutant or transgenic tobacco plants or parts thereof, or ODC mutant or transgenic tobacco plants or parts thereof, capable of producing a leaf comprising a comparable leaf yield relative to a comparable leaf of a control plant not comprising the same mutation or transgene.
- a comparable leaf yield is within 20%, 17.5%, 15%, 12.5%, 10%, 7.5%, 5%, 2.5%, or 1% of the level in a comparable leaf of a control plant not comprising the same mutation or transgene.
- a comparable leaf yield is between 0.5% and 1%, between 1% and 2%, between 2% and 3%, between 3% and 4%, between 4% and 5%, between 5% and 6%, between 6% and 7%, between 7% and 8%, between 8% and 9%, between 9% and 10%, between 11% and 12%, between 12% and 13%, between 13% and 14%, between 14% and 15%, between 15% and 16%, between 16% and 17%, between 17% and 18%, between 18% and 19%, or between 19% and 20% of the level in a comparable leaf of a control plant not comprising the same mutation or transgene.
- a comparable leaf yield is between 0.5% and 5%, between 5% and 10%, or between 10% and 20% of the level in a comparable leaf of a control plant not comprising the same mutation or transgene.
- the present disclosure provides ADC mutant or transgenic tobacco plants or parts thereof, AO mutant or transgenic tobacco plants or parts thereof, or ODC mutant or transgenic tobacco plants or parts thereof, exhibiting a comparable insect herbivory susceptibility relative to a comparable leaf of a control plant not comprising the same mutation or transgene.
- a comparable insect herbivory susceptibility is within 20%, 17.5%, 15%, 12.5%, 10%, 7.5%, 5%, 2.5%, or 1% of the level in a comparable leaf of a control plant not comprising the same mutation or transgene.
- a comparable insect herbivory susceptibility is between 0.5% and 1%, between 1% and 2%, between 2% and 3%, between 3% and 4%, between 4% and 5%, between 5% and 6%, between 6% and 7%, between 7% and 8%, between 8% and 9%, between 9% and 10%, between 11% and 12%, between 12% and 13%, between 13% and 14%, between 14% and 15%, between 15% and 16%, between 16% and 17%, between 17% and 18%, between 18% and 19%, or between 19% and 20% of the level in a comparable leaf of a control plant not comprising the same mutation or transgene.
- a comparable insect herbivory susceptibility is between 0.5% and 5%, between 5% and 10%, or between 10% and 20% of the level in a comparable leaf of a control plant not comprising the same mutation or transgene.
- Insect herbivory susceptibility level can be assayed by methods known in the art, for example, in an insect feeding assay.
- a quarter inch layer of 0.7% agar in water is added to a 100 mm Petri dish and allowed to solidify.
- Leaf discs are cut from the petri dish lid, placed in the plates and pushed gently into the agar.
- Leaf discs are taken from plants at the 4-5 leaf stage. Discs were taken from lamina only to exclude major midribs.
- a single disc is taken from each of the four largest leaves of the plant generating 4 replicates per plant. Four plants are sampled for a total of 16 biological replicates test line.
- a single budworm (e.g., Heliothis sp., Helicoverpa sp.) at the second instar stage is added to the leaf and allowed to feed for 48 hours at ambient temperature. After 48 hours the budworm larvae are weighed and final larval weights are recorded.
- budworm e.g., Heliothis sp., Helicoverpa sp.
- a tobacco plant comprises relative to a control tobacco plant: a first genome modification providing a lower level of nicotine or total alkaloid (e.g., in or targeting one or more ADC, AO, or ODC genes), and a second genome modification providing a comparable level of one or more traits selected from the group consisting of total leaf polyamine level, total root polyamine level, total leaf chlorophyll level, mesophyll cell number per leaf area unit, and leaf epidermal cell size; and where the control plant does not have both the first and the second genome modifications.
- a first genome modification providing a lower level of nicotine or total alkaloid (e.g., in or targeting one or more ADC, AO, or ODC genes)
- a second genome modification providing a comparable level of one or more traits selected from the group consisting of total leaf polyamine level, total root polyamine level, total leaf chlorophyll level, mesophyll cell number per leaf area unit, and leaf epidermal cell size; and where the control plant does not have both the first and the second genome
- a tobacco plant, or part thereof comprises relative to a control tobacco plant: a first genome modification providing a lower level of nicotine or total alkaloid (e.g., in or targeting one or more ADC, AO, or ODC genes), and a second genome modification providing a comparable level of total leaf polyamine level, where the control plant does not have both the first and the second genome modifications.
- a tobacco plant, or part thereof comprises relative to a control tobacco plant: a first genome modification providing a lower level of nicotine or total alkaloid (e.g., in or targeting one or more ADC, AO, or ODC genes), and a second genome modification providing a comparable level of total root polyamine level, where the control plant does not have both the first and the second genome modifications.
- a tobacco plant comprises relative to a control tobacco plant: a first genome modification providing a lower level of nicotine or total alkaloid (e.g., in or targeting one or more ADC, AO, or ODC genes), and a second genome modification providing a comparable level of mesophyll cell number per leaf area unit, where the control plant does not have both the first and the second genome modifications.
- a first genome modification providing a lower level of nicotine or total alkaloid (e.g., in or targeting one or more ADC, AO, or ODC genes)
- a second genome modification providing a comparable level of mesophyll cell number per leaf area unit, where the control plant does not have both the first and the second genome modifications.
- a tobacco plant, or part thereof comprises relative to a control tobacco plant: a first genome modification providing a lower level of nicotine or total alkaloid (e.g., in or targeting one or more ADC, AO, or ODC genes), and a second genome modification providing a comparable level of leaf epidermal cell size, where the control plant does not have both the first and the second genome modifications.
- a second genome modification is in or targeting an ADC, AO, or ODC gene.
- a first genome modification, a second genome modification, or both comprise a transgene, a mutation, or both.
- a genome modification, a second genome modification, or both comprise a transgene.
- a first genome modification, a second genome modification, or both comprise a mutation.
- a first genome modification, a second genome modification, or both are not transgene-based.
- a first genome modification, a second genome modification, or both are not mutation-based.
- tobacco plants provided herein comprise a reduced amount of total conjugated polyamines in leaves relative to the control tobacco plant. In one aspect, tobacco plants provided herein comprise a reduced amount of total conjugated polyamines in roots relative to the control tobacco plant.
- conjugated polyamines include, but are not limited to, soluble conjugated polyamines such as phenolamides containing a backbone consisting of a free polyamine (e.g., putrescine, spermine, and/or spermidine) conjugated with one or more phenylpropanoids such as ferulic, caffeic and courmaric acids.
- Conjugated polyamines also include, but are not limited to, insoluble conjugated polyamines incorporated into structural polymers such as lignin.
- tobacco plants provided herein comprise a reduced amount of total free polyamines (e.g., putrescine, spermine, and spermidine) in leaves relative to the control tobacco plant.
- tobacco plants provided herein comprise a reduced amount of total conjugated polyamines in roots relative to the control tobacco plant.
- tobacco plants provided herein comprise a reduced amount of total conjugated form of one or more polyamines selected from the group consisting of putrescine, spermidine and spermine in leaves relative to the control tobacco plant.
- tobacco plants provided herein comprise a reduced amount of total conjugated form of one or more polyamines selected from the group consisting of putrescine, spermidine and spermine in roots relative to the control tobacco plant. In an aspect, tobacco plants provided herein comprise a reduced amount of total free form of one or more polyamines selected from the group consisting of putrescine, spermidine and spermine in leaves relative to the control tobacco plant. In one aspect, tobacco plants provided herein comprise a reduced amount of total conjugated form of one or more polyamines selected from the group consisting of putrescine, spermidine and spermine in roots relative to the control tobacco plant.
- a characteristic or a trait of a tobacco plant described here are measured at a time selected from the group consisting of immediately before flowering, at topping, 1 week- post-topping (WPT), 2 WPT, 3 WPT, 4 WPT, 5 WPT, 6 WPT, 7 WPT, 8 WPT, and at harvest.
- tobacco plants provided herein comprising a first and a second genome modification are capable of producing a leaf with a leaf grade comparable to that of a leaf from a control plant.
- tobacco plants provided herein comprising a first and a second genome modification have a total leaf yield comparable to a control plant.
- a tobacco plant of the present disclosure comprises a nicl mutation, a nic2 mutation, or both.
- a modified tobacco plant provided herein further comprises a transgene or mutation directly suppressing the expression or activity of one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more, fifteen or more, sixteen or more, or seventeen or more genes or loci encoding a protein selected from the group consisting of agmatine deiminase (AIC), arginase, diamine oxidase, methylputrescine oxidase (MPO), NADH dehydrogenase, phosphoribosylanthranilate isomerase (PRAI), putrescine N- methyltransferase (PMT), quinolate phosphoribosyl transferase (QPT), S-adenosyl-methionine synthetase (SAMS), A622, NBB1, ber
- a modified tobacco plant provided herein further comprises a mutation in an ERF gene of Nic2 locus (Nic2_ERF).
- a modified tobacco plant provided herein further comprises one or more mutations in one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or all ten genes selected from the group consisting of ERF32, ERF34, ERF39, ERF189, ERF115, ERF221, ERF104, ERF179, ERF17, and ERF168.
- a modified tobacco plant provided herein further comprises one or more mutations in ERF189, ERF115, or both.
- a modified tobacco plant provided herein further comprises one or more transgenes targeting and suppressing a gene encoding one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or all ten proteins selected from the group consisting oiERF32, ERF34, ERF39, ERF189, ERF115, ERF221, ERF104, ERF179, ERF17, and ERF168.
- a modified tobacco plant provided herein further comprises a mutation in an ERF gene of Nicl locus (Nicl_ERF) (or Niclb locus as in WO/2019/140297). See also WO/2018/237107.
- a modified tobacco plant provided herein further comprises one or more mutations in two or more, three or more, four or more, five or more, six or more, or seven or more genes selected from the group consisting of ERF 101, ERF 110, ERFnew, ERF 199, ERF 19, ERF130, ERF16, ERF29, ERF210, and ERF91L2. See WO/2019/140297 and Kajikawa et al., Plant physiol. 2017, 174:999-1011.
- a modified tobacco plant provided herein further comprises one or more mutations in one or more, two or more, three or more, four or more, five or more, or all six genes selected from the group consisting of ERFnew, ERF 199, ERF 19, ERF29, ERF210, and ERF91L2.
- a modified tobacco plant provided herein further comprises one or more transgenes targeting and suppressing a gene encoding one or more, two or more, three or more, four or more, five or more, six or more, or seven or more genes selected from the group consisting of ERFlOl, ERF110, ERFnew, ERF199, ERF19, ERF130, ERF16, ERF29, ERF210, and ERF91L2.
- a modified tobacco plant provided herein further comprise a first genetic modification comprising a mutation in a gene or locus encoding a protein selected from the group consisting of aspartate oxidase, agmatine deiminase (AIC), arginase, diamine oxidase, arginine decarboxylase (ADC), methylputrescine oxidase (MPO), NADH dehydrogenase, ornithine decarboxylase (ODC), phosphoribosylanthranilate isomerase (PRAI), putrescine N-methyltransferase (PMT), quinolate phosphoribosyl transferase (QPT), and S-adenosyl- methionine synthetase (SAMS), A622, NBB1, BBL, MYC2, Nicl_ERF, Nic2_ERF, ethylene response factor (ERF) transcription factor, nicotine uptake permease
- AIC aspartate
- this disclosure provides a method comprising preparing a tobacco product using cured tobacco material from a modified tobacco plant, where the modified tobacco plant comprises a non-natural mutation in an endogenous nucleic acid sequence encoding a polypeptide comprising an amino acid sequence at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- this disclosure provides a method comprising preparing a tobacco product using cured tobacco material from a modified tobacco plant, where the modified tobacco plant comprises a non-natural mutation in an endogenous nucleic acid sequence at least 80% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 -6.
- this disclosure provides a method comprising preparing a tobacco product using cured tobacco material from a modified tobacco plant, where the modified tobacco plant comprises a non-natural mutation in an endogenous nucleic acid sequence at least 80% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7-12.
- this disclosure provides a method comprising preparing a tobacco product using cured tobacco material from a modified tobacco plant, where the modified tobacco plant comprises a recombinant DNA construct, where the recombinant DNA construct comprises a heterologous promoter operably linked to a nucleic acid sequence encoding at least one small RNA molecule capable of binding to and reducing the expression of at least one endogenous nucleic acid sequence encoding a polypeptide at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- this disclosure provides a method comprising preparing a tobacco product using cured tobacco material from a modified tobacco plant, where the modified tobacco plant comprises a recombinant DNA construct, and where the recombinant DNA construct comprises a heterologous promoter operably linked to a nucleic acid sequence encoding at least one small RNA molecule capable of binding to and reducing the expression of at least one endogenous nucleic acid sequence at least 80% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-6.
- this disclosure provides a method comprising preparing a tobacco product using cured tobacco material from a modified tobacco plant, where the modified tobacco plant comprises a recombinant DNA construct, and where the recombinant DNA construct comprises a heterologous promoter operably linked to a nucleic acid sequence encoding at least one small RNA molecule capable of binding to and reducing the expression of at least one endogenous nucleic acid sequence at least 80% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7-12.
- this disclosure provides a method comprising preparing a tobacco plant using cured tobacco material from a modified tobacco plant, where the modified tobacco plant comprises a recombinant DNA construct, and where the recombinant DNA construct comprises a heterologous promoter operably linked to a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18.
- this disclosure provides a method comprising preparing a tobacco plant using cured tobacco material from a modified tobacco plant, where the modified tobacco plant comprises a recombinant DNA construct, and where the recombinant DNA construct comprises a heterologous promoter operably linked to a nucleic acid sequence at least 80% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-6.
- this disclosure provides a method comprising preparing a tobacco plant using cured tobacco material from a modified tobacco plant, where the modified tobacco plant comprises a recombinant DNA construct, and where the recombinant DNA construct comprises a heterologous promoter operably linked to a nucleic acid sequence at least 80% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 7-12.
- “Curing” is the aging process that reduces moisture and brings about the destruction of chlorophyll giving tobacco leaves a golden color and by which starch is converted to sugar. Cured tobacco therefore has a higher reducing sugar content and a lower starch content compared to harvested green leaf.
- tobacco plants or plant components provided herein can be cured using conventional means, e.g., flue-cured, barn-cured, fire-cured, air-cured or sun-cured. See, for example, Tso (1999, Chapter 1 in Tobacco, Production, Chemistry and Technology, Davis & Nielsen, eds., Blackwell Publishing, Oxford) for a description of different types of curing methods.
- Cured tobacco is usually aged in a wooden drum (e.g., a hogshead) or cardboard cartons in compressed conditions for several years (e.g., two to five years), at a moisture content ranging from 10% to about 25%. See, U.S. Patent Nos. 4,516,590 and 5,372,149. Cured and aged tobacco then can be further processed. Further processing includes conditioning the tobacco under vacuum with or without the introduction of steam at various temperatures, pasteurization, and fermentation. [00233] Information regarding the harvesting of burley and dark tobacco varieties can be found in the 2019-2020 Burley and Dark Tobacco Production Guide (December 2018) published by the University of Kentucky, The University of Tennessee, Virginia Tech, and North Carolina State University, which is incorporated herein by reference in its entirety.
- this disclosure provides cured tobacco material from any tobacco plant, or part thereof, provided herein. In an aspect, this disclosure provides cured tobacco material from any modified tobacco plant, or part thereof, provided herein.
- cured tobacco material comprises tobacco material selected from the group selected from cured leaf material, cured stem material, cured bud material, cured flower material, and cured root material.
- cured tobacco material comprises cured leaf material, cured stem material, or both.
- cured tobacco material comprises cured leaf material.
- cured tobacco material comprises cured stem material.
- cured tobacco material comprises flue-cured tobacco material.
- cured tobacco material comprises air-cured tobacco material.
- cured tobacco material comprises fire-cured tobacco material.
- cured tobacco material comprises sun-cured tobacco material.
- cured tobacco material provided herein is selected from the group consisting of air-cured tobacco material, fire-cured tobacco material, sun-cured tobacco material, and flue-cured tobacco material.
- cured tobacco material is from a tobacco variety selected from the group consisting of a flue-cured variety, a bright variety, a Burley variety, a Virginia variety, a Maryland variety, a dark variety, an Oriental variety, and a Turkish variety.
- cured tobacco leaf provided herein is selected from the group consisting of air-cured tobacco leaf, fire-cured tobacco leaf, sun-cured tobacco leaf, and flue-cured tobacco leaf.
- cured tobacco leaf is from a tobacco variety selected from the group consisting of a flue-cured variety, a bright variety, a Burley variety, a Virginia variety, a Maryland variety, a dark variety, an Oriental variety, and a Vietnamese variety.
- Fermentation typically is characterized by high initial moisture content, heat generation, and a 10 to 20% loss of dry weight. See, for example, U.S. Patent Nos. 4,528,993, 4,660,577, 4,848,373, 5,372,149; U.S. Publication No. 2005/0178398; and Tso (1999, Chapter 1 in Tobacco, Production, Chemistry and Technology, Davis & Nielsen, eds., Blackwell Publishing, Oxford). Cured, aged, and fermented tobacco can be further processed (e.g., cut, shredded, expanded, or blended). See, for example, U.S. Patent Nos. 4,528,993; 4,660,577; and 4,987,907.
- this disclosure provides fermented tobacco material from any tobacco plant, or part thereof, provided herein.
- this disclosure provides fermented tobacco material from any modified tobacco plant, or part thereof, provided herein.
- Tobacco products derived from plants of the present disclosure also include cigarettes and other smoking articles, particularly those smoking articles including filter elements, where the rod of smokable material includes cured tobacco within a tobacco blend.
- a tobacco product of the present disclosure is selected from the group consisting of a cigarillo, a non-ventilated recess filter cigarette, a vented recess filter cigarette, a cigar, snuff, pipe tobacco, cigar tobacco, cigarette tobacco, chewing tobacco, leaf tobacco, hookah tobacco, shredded tobacco, and cut tobacco.
- a tobacco product of the present disclosure is selected from the group consisting of a cigarette, a heated tobacco product, a kretek, a bidi cigarette, a cigar, a cigarillo, a non-ventilated cigarette, a vented recess filter cigarette, pipe tobacco, snuff, snus, chewing tobacco, moist smokeless tobacco, fine cut chewing tobacco, long cut chewing tobacco, pouched chewing tobacco product, gum, a tablet, a lozenge, and a dissolving strip.
- the modified tobacco plant, or part thereof, of embodiment 1 wherein said at least one non-natural mutation results in a reduced level of activity by a protein or polypeptide encoded by said nucleic acid sequence as compared to activity of a protein or polypeptide encoded by said nucleic acid sequence in a control tobacco plant when grown under comparable conditions, wherein said nucleic acid sequence lacks the at least one non- natural mutation in said control tobacco plant.
- said promoter comprises a promoter selected from the group consisting of a constitutive promoter, a tissue-preferred promoter, a tissue-specific promoter, and an inducible promoter.
- siRNA small interfering RNA
- a /raw.s-acting siRNA a microRNA.
- said at least one small RNA molecule comprises between 18 nucleotides and 30 nucleotides.
- said at least one small RNA molecule comprises a nucleic acid sequence at least 90% complementary to a sequence selected from the group consisting of SEQ ID NOs: 7-12.
- step (d) growing said modified tobacco plant regenerated in step (c).
- step (c) growing said modified tobacco plant regenerated in step (c).
- step (c) growing said modified tobacco plant regenerated in step (c).
- step (c) growing said modified tobacco plant regenerated in step (c).
- step (c) growing said modified tobacco plant regenerated in step (c).
- step (c) growing said modified tobacco plant regenerated in step (c).
- any one of embodiments 52 to 89 wherein said modified tobacco plant is of a variety selected from the group consisting of the varieties listed in Tables 2, 3, 4, 5, 6, 7, and 8.
- the method of any one of embodiments 52 to 92, wherein said modified tobacco plant is female sterile.
- said modified tobacco plant comprises a comparable or higher USDA leaf grade index as compared to a control tobacco plant lacking said non-natural mutation when grown under comparable conditions.
- a method comprising preparing a tobacco product using cured tobacco material from a modified tobacco plant, wherein said modified tobacco plant comprises a recombinant DNA construct, and wherein said recombinant DNA construct comprises a heterologous promoter operably linked to a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. .
- said cured tobacco material comprises flue-cured tobacco material, air-cured tobacco material, fire-cured tobacco material, and sun-cured tobacco material.
- said tobacco product is selected from the group consisting of a cigarette, a kretek, a bidi cigarette, a cigar, a cigarillo, a non-ventilated cigarette, a vented recess filter cigarette, pipe tobacco, snuff, snus, chewing tobacco, moist smokeless tobacco, fine cut chewing tobacco, long cut chewing tobacco, pouched chewing tobacco product, gum, a tablet, a lozenge, and a dissolving strip.
- any one of embodiments 97 to 99, wherein said tobacco product is a smokeless tobacco product.
- said smokeless tobacco product is selected from the group consisting of loose leaf chewing tobacco, plug chewing tobacco, moist snuff, nasal snuff, dry snuff, and snus.
- said cured tobacco material is of a tobacco variety selected from the group consisting of a flue-cured variety, a bright variety, a Burley variety, a Virginia variety, a Maryland variety, a dark variety, a Galpao variety, an Oriental variety, and a Turkish variety.
- a method comprising transforming a tobacco cell with a recombinant DNA construct, wherein said recombinant DNA construct comprises a heterologous promoter operably linked to a nucleic acid sequence encoding at least one small RNA molecule capable of binding to and reducing the expression of at least one endogenous nucleic acid sequence encoding a polypeptide at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. .
- a method comprising transforming a tobacco cell with a recombinant DNA construct, wherein said recombinant DNA construct comprises a heterologous promoter operably linked to a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence at least 80% identical or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18. .
- a method for producing a modified tobacco plant comprising:
- a method for producing a modified tobacco plant comprising:
- a method for producing a modified tobacco plant comprising:
- step (b) selecting for at least one progeny tobacco seed, or a plant germinated therefrom, wherein said at least one tobacco seed or plant germinated therefrom comprises said recombinant DNA construct.
- the method of embodiment 113, wherein said at least one alkaloid is selected from the group consisting of anabasine, anatabine, nicotine, and nornicotine. .
- the method of embodiment 113 or 114, wherein said reduced amount of at least one alkaloid comprises a reduction of at least 1%. .
- invention 110 or 111 wherein said endogenous nucleic acid sequence comprises a sequence at least 80% identical to a sequence selected from the group consisting of SEQ ID NOs: 1 to 12. .
- the modified tobacco plant, or part thereof, of embodiment 118 wherein said endogenous nucleic acid sequence encodes a transcription factor that is capable of binding to a nucleic acid sequence encoding said gene. .
- the modified tobacco plant, or part thereof, of embodiment 118, wherein said endogenous nucleic acid sequence encodes a protein that generates a precursor or substrate required for said polypeptide to function. .
- the modified tobacco plant, or part thereof, of embodiment 118 wherein said expression or functional activity is increased expression or activity as compared to a control tobacco plant lacking said at least one non-natural mutation when grown under comparable conditions.
- 124. The modified tobacco plant, or part thereof, of embodiment 118, wherein said tobacco plant produces a leaf comprising a reduced amount of at least one alkaloid as compared to the amount of said alkaloid in a control tobacco plant lacking said at least one non-natural mutation in said endogenous nucleic acid sequence when grown under comparable conditions.
- a tobacco blend comprising the cured tobacco material of embodiment 125.
- a tobacco product comprising the tobacco blend of embodiment 126.
- a tobacco product comprising the cured tobacco material of embodiment 125.
- a reconstituted tobacco comprising the cured tobacco material of embodiment 125.
- a modified tobacco plant comprising: (a) a genetic modification in a gene; or (b) a genetic modification targeting said gene; wherein said genetic modification downregulates the expression or activity of said gene, wherein said gene encodes a nucleic acid sequence having at least 80% identity to a polynucleotide sequence selected from the group consisting of SEQ ID NOs: 1 to 12.
- decarboxylases Of the 189 decarboxylases identified, only two types of decarboxylases are known to act on a substrate comprising a six-membered ring: aromatic amino acid decarboxylases and tyrosine decarboxylases. Of the 189 identified decarboxylases, three decarboxylases are annotated as aromatic amino acid decarboxylases, and ten decarboxylases are annotated as tyrosine decarboxylases. After curating the thirteen decarboxylases, including removing enzyme isoforms, six decarboxylases are identified for further examination. See Table 9.
- RNA is extracted from the root samples, and cDNA transcripts are generated from the RNA samples, using methods standard in the art. The resulting cDNA is used to measure the relative expression of each candidate gene with quantitative RT-PCR (qRT-PCR) using genespecific primers. See Table 10.
- An expression vector is used as a backbone to generate multiple transformation vectors comprising recombinant DNA constructs (SEQ ID NO: 31).
- the expression vector contains a Cassava Vein Mosaic Virus (CsVMV) promoter, a NOS terminator, and a cassette comprising a kanamycin selection marker (NPT II) operably linked to an Actin2 promoter and a NOS terminator.
- Nucleic acid vectors comprising transgenes of interest e.g., SEQ ID NOs: 1 to 12
- TN90 tobacco plants are grown in MagentaTM GA- 7 boxes and leaf discs are cut and placed into Petri plates.
- Agrobacterium tumefaciens cells comprising a transformation vector are collected by centrifuging a 20 mL cell suspension in a 50 mL centrifuge tube at 3500 RPM for 10 minutes. The supernatant is removed and the Agrobacterium tumefaciens cell pellet is resuspended in 40 mL liquid re-suspension medium.
- Tobacco leaves, avoiding the midrib are cut into eight 0.6 cm discs with a #15 razor blade and placed upside down in a Petri plate.
- Leaf discs are transferred to co-cultivation Petri plates (1/2 MS medium) and discs are placed upside down in contact with filter paper overlaid on the co-cultivation TOM medium (MS medium with 20 g/L sucrose; 1 mg/L indole-3 -acetic acid; and 2.5 mg/L 6-benzyl aminopurine (BAP)).
- the Petri plate is sealed with parafilm prior to incubation in dim light (60- 80 mE/ms) with 18 hours on, 6 hours off photoperiods at 24 degrees Celsius for three days. After incubation, leaf discs are transferred to regeneration/selection TOM K medium Petri plates (TOM medium plus 300 mg/L kanamycin).
- Modified tobacco plants from Example 3, along with controls, are grown in 25 centimeter pots in a greenhouse with 75 parts per million fertilizer. At flowering stage, plants are topped. Two weeks after topping, lamina samples are collected from the third, fourth, and fifth leaves from the top of the plant, and alkaloid levels are measured using a method in accordance with CORESTA Method No 62, Determination of Nicotine in Tobacco and Tobacco Products by Gas Chromatographic Analysis, February 2005, and those defined in the Centers for Disease Control and Prevention’s Protocol for Analysis of Nicotine, Total Moisture and pH in Smokeless Tobacco Products, as published in the Federal Register Vol. 64, No. 55 March 23, 1999 (and as amended in Vol. 74, No. 4, January 7, 2009).
- Plants are also planted in the field, harvested, and tested for alkaloids and TSNA levels in cured tobacco. Both leaf yield and leaf grade are also assessed for modified plants.
- CsVMV Cassava Vein Mosaic Virus
- Hairy root cultures can serve as an alternative to plant cell suspensions and serve as useful proxies for whole plants when studying secondary metabolites. See, for example, Zhou et al., Appl. Microbiol Biotechnol., 90:1229-1239 (2011) and Hidalgo et al., Scientific Reports, 7:45331 (2017) for additional information regarding hairy root cultures.
- Transformation and hairy root induction is performed as described in Hidalgo et al., Scientific Reports, 7 7976 (2017). Briefly, leaf discs from tobacco plantlets are grown in vitro on MS medium. The leaf discs are co-infected with Agrobacterium rhizogenes line ATCC15834 to introduce the transformation vectors described above and to induce hairy root formation. Approximately two to four weeks after transformation, hairy roots appear in leaf discs grown on solid MS medium comprising 30 grams per liter (g/L) sucrose and 500 milligrams per liter (mg/L) cefotaxime.
- Hairy roots are then excised and individually cultured on solid MS medium comprising 30 g/L sucrose, 500 mg/L cefotaxime, and 50 mg/L kanamycin to select for hairy root cultures that are successfully transformed.
- Transformed hairy root cultures are grown in the dark at 25°C. Approximately two to three weeks later, liquid cultures are inoculated with transgenic roots and are grown at 25°C until they are used in further analyses.
- Table 11 provides the relative expression of each overexpressed candidate gene as compared to the expression of tobacco eukaryotic translation elongation factor 1 alpha (EFla; SEQ ID NO: 34) in dark tobacco hairy root cultures.
- EFla tobacco eukaryotic translation elongation factor 1 alpha
- Table 11 Relative expression of overexpressed genes as compared to tobacco EFla (Data for EFla is not shown, but is set to 1. Values over 1 indicate higher expression relative to EFla, and values below 1 indicate lower expression relative to EFla). Expression as compared to control is determined by dividing the relative expression of the overexpressed gene in the experimental lines by the relative expression of the relevant control line.
- Alkaloid levels are also measured in the hairy root cultures that are overexpressing a candidate gene discussed above in Example 5 and control hairy root cultures comprising an empty vector.
- Table 17 Anabasine levels measured in hairy root cultures that are overexpressing a candidate gene. All anabasine levels are in milligrams per gram of dry weight.
- Separate transformation vectors comprising an artificial miRNA designed to reduce the transcription or translation of one each of SEQ ID NOs: 7-12 driven by CsVMV are constructed using the vector described in Example 3.
- An additional transformation vector is generated to simultaneously target g66856 (SEQ ID NO: 7) and gl l429 (SEQ ID NO: 12) using a miRNA construct (SEQ ID NO: 32) driven by a CsVMV promoter as described in Example 3.
- Another transformation vector is generated to simultaneously target g44542 (SEQ ID NO: 9) and g8073 (SEQ ID NO: 8) using a miRNA construct (SEQ ID NO: 33) driven by a CsVMV promoter as described in Example 3.
- Tobacco lines plants or hairy root cultures) expressing these RNAi constructs are collectively referred to as “knockdown lines” below.
- the vectors are used to (a) transform dark tobacco hairy root cultures using the Agrobacterium rhizogenes line ATCC15834 as described in Example 5 and/or (b) generate modified tobacco plants as described in Example 3. Control hairy root cultures and control modified tobacco plants are transformed with an “empty” vector that lacks the miRNA constructs.
- Table 18 provides the relative expression of each candidate gene as compared to the expression of tobacco eukaryotic translation elongation factor 1 alpha (EFla; SEQ ID NO: 34) in dark tobacco hairy root cultures that express either SEQ ID NO: 32 or SEQ ID NO: 33 under the control of a CsVMV promoter. For each of Tables 18, 19, and 20, expression is measured using qRT-PCR, and the values shown are averages from three biological replicates for each line.
- Table 18 Relative expression of candidate genes as compared to tobacco EFla in hairy root culture knockdown lines. (Data for EFl a is not shown, but is set to 1. Values over 1 indicate higher expression relative to EFla, and values below 1 indicate lower expression relative to EFla). Expression as compared to control is determined by dividing the relative expression of the candidate gene in the knockdown lines by the relative expression of the relevant control line. SEQ ID NO: 32 targets g66856 and gl 1429, while SEQ ID NO: 33 targets g44542 and g8073.
- Table 19 Relative expression of QPT in hairy root cultures knockdown lines as compared to tobacco EFla (Data for EF 1 a is not shown, but is set to 1. Values over 1 indicate higher expression relative to EFla, and values below 1 indicate lower expression relative to EFla). Expression as compared to control is determined by dividing the relative expression of QPT in the overexpression lines by the relative expression of the relevant control line. SEQ ID NO: 32 targets g66856 and gl 1429, while SEQ ID NO: 33 targets g44542 and g8073. Table 20. Relative expression of PMT in hairy root cultures knockdown lines as compared to tobacco EFla (Data for EF 1 a is not shown, but is set to 1.
- Expression as compared to control is determined by dividing the relative expression of PMT in the overexpression lines by the relative expression of the relevant control line.
- SEQ ID NO: 32 targets g66856 and gl 1429, while SEQ ID NO: 33 targets g44542 and g8073.
- Example 8 Measuring alkaloid content in transformed tobacco hairy root culture knockdown lines
- Alkaloid levels are measured in hairy root culture knockdown lines using the method described above in Example 6. Results are shown in Tables 21-24, and the values are averages measured in three biological replicates for each line. Percent change compared to control in Tables 21-24 is calculated by using the formula: ((Control Level - Overexpression Line Level) / (Control Level)) x 100 for each measured alkaloid. Negative values derived from this formula are depicted as increases, and positive values as decreases.
- Table 23 Anatabine levels measured in hairy root culture knockdown lines. All anatabine levels are in milligrams per gram of dry weight.
- Table 24 Anabasine levels measured in hairy root culture knockdown lines. All anabasine levels are in milligrams per gram of dry weight.
- Modified tobacco plants (TO generation) comprising the aforementioned knockdown constructs are generated and grown as described in Example 3. Then, the resulting modified plants are topped, and alkaloid levels are measured as described in Example 4.
- Mutations are produced in each of the genes identified in Table 9 by specifically editing SEQ ID NOs: 1-6, separately, in the tobacco genome. Higher order mutants are also produced (e.g., a double mutant comprising a mutation in each of SEQ ID NOs: 1 and 6; a double mutant comprising a mutation in each of SEQ ID NOs: 2 and 3; a quadruple mutant comprising a mutation in each of SEQ ID NOs: 1, 2, 3, and 6; a sextuple mutant comprising a mutation in each of SEQ ID NOs: 1-6).
- Tobacco protoplasts are transfected using polyethylene glycol (PEG) with plasmids encoding a CRISPR protein or a CRISPR protein and specific guide RNA (gRNA) targeting individual genes at desired positions.
- PEG polyethylene glycol
- gRNA specific guide RNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
La présente divulgation concerne des plantes de tabac, des parties de plantes, des graines, des compositions et des procédés liés à la modulation de l'expression des gènes de la décarboxylase dans le tabac pour réguler les niveaux d'alcaloïdes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263344837P | 2022-05-23 | 2022-05-23 | |
US63/344,837 | 2022-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023230433A1 true WO2023230433A1 (fr) | 2023-11-30 |
Family
ID=86942316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/067281 WO2023230433A1 (fr) | 2022-05-23 | 2023-05-22 | Procédés et compositions pour la régulation des alcaloïdes dans le domaine du tabac |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023230433A1 (fr) |
Citations (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4516590A (en) | 1982-11-26 | 1985-05-14 | Philip Morris Incorporated | Air-cured bright tobacco filler, blends and smoking articles |
US4528993A (en) | 1982-08-20 | 1985-07-16 | R. J. Reynolds Tobacco Company | Process for producing moist snuff |
US4660577A (en) | 1982-08-20 | 1987-04-28 | R.J. Reynolds Tobacco Company | Dry pre-mix for moist snuff |
US4848373A (en) | 1987-04-13 | 1989-07-18 | Helme Tobacco Company | Nicotine removal process and product produced thereby |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4987907A (en) | 1988-06-29 | 1991-01-29 | Helme Tobacco Company | Chewing tobacco composition and process for producing same |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
WO1991016024A1 (fr) | 1990-04-19 | 1991-10-31 | Vical, Inc. | Lipides cationiques servant a l'apport intracellulaire de molecules biologiquement actives |
WO1991017424A1 (fr) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Acheminement intracellulaire de substances biologiquement actives effectue a l'aide de complexes de lipides s'auto-assemblant |
US5159135A (en) | 1986-12-03 | 1992-10-27 | Agracetus | Genetic engineering of cotton plants and lines |
US5188958A (en) | 1986-05-29 | 1993-02-23 | Calgene, Inc. | Transformation and foreign gene expression in brassica species |
US5372149A (en) | 1992-03-25 | 1994-12-13 | Roth; David S. | Sterilization process in the manufacturing of snuff |
US5538880A (en) | 1990-01-22 | 1996-07-23 | Dekalb Genetics Corporation | Method for preparing fertile transgenic corn plants |
US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
US5591616A (en) | 1992-07-07 | 1997-01-07 | Japan Tobacco, Inc. | Method for transforming monocotyledons |
US5750871A (en) | 1986-05-29 | 1998-05-12 | Calgene, Inc. | Transformation and foreign gene expression in Brassica species |
US5824877A (en) | 1988-07-22 | 1998-10-20 | Monsanto Company | Method for soybean transformation and regeneration |
US6153812A (en) | 1994-10-26 | 2000-11-28 | Monsanto Company | Rapid and efficient regeneration of transgenic wheat plants |
US6160208A (en) | 1990-01-22 | 2000-12-12 | Dekalb Genetics Corp. | Fertile transgenic corn plants |
US6194636B1 (en) | 1999-05-14 | 2001-02-27 | Dekalb Genetics Corp. | Maize RS324 promoter and methods for use thereof |
US6232526B1 (en) | 1999-05-14 | 2001-05-15 | Dekalb Genetics Corp. | Maize A3 promoter and methods for use thereof |
US6384301B1 (en) | 1999-01-14 | 2002-05-07 | Monsanto Technology Llc | Soybean agrobacterium transformation method |
US6399861B1 (en) | 1990-04-17 | 2002-06-04 | Dekalb Genetics Corp. | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
WO2004041006A1 (fr) | 2002-10-31 | 2004-05-21 | R.J. Reynolds Tobacco Company | Melanges de tabacs comprenant des tabacs orientaux |
US20040216189A1 (en) | 2001-01-09 | 2004-10-28 | Nancy Houmard | Maize chloroplast aldolase promoter compositions and methods for use thereof |
US20050178398A1 (en) | 2003-12-22 | 2005-08-18 | U.S. Smokeless Tobacco Company | Conditioning process for tobacco and/or snuff compositions |
US20060191548A1 (en) | 2003-11-07 | 2006-08-31 | Strickland James A | Tobacco compositions |
US20060200878A1 (en) | 2004-12-21 | 2006-09-07 | Linda Lutfiyya | Recombinant DNA constructs and methods for controlling gene expression |
WO2011027315A1 (fr) | 2009-09-04 | 2011-03-10 | Moshe Danny S | Classement de produits agricoles par analyse et imagerie hyperspectrales |
US8124851B2 (en) | 2007-11-12 | 2012-02-28 | North Carolina State University | Alteration of tobacco alkaloid content through modification of specific cytochrome P450 genes |
US8319011B2 (en) | 2006-12-15 | 2012-11-27 | U.S. Smokeless Tobacco Company Llc | Tobacco plants having reduced nicotine demethylase activity |
US9187759B2 (en) | 2005-02-23 | 2015-11-17 | North Carolina State University | Alteration of tobacco alkaloid content through modification of specific cytochrome P450 genes |
US9247706B2 (en) | 2010-01-15 | 2016-02-02 | North Carolina State University | Compositions and methods for minimizing nornicotine synthesis in tobacco |
WO2018067985A1 (fr) | 2016-10-07 | 2018-04-12 | Altria Client Services Llc | Compositions et procédés de production de plants de tabac et de produits ayant une teneur réduite en nitrosamines spécifiques du tabac |
WO2018222667A1 (fr) * | 2017-05-31 | 2018-12-06 | 22Nd Century Limited, Llc | Procédés d'édition génomique pour produire des produits de tabac à faible teneur en nicotine |
WO2018237107A1 (fr) | 2017-06-23 | 2018-12-27 | University Of Kentucky Research Foundation | Procédé |
WO2019140297A1 (fr) | 2018-01-12 | 2019-07-18 | Altria Client Services Llc | Compositions et procédés de production de plants de tabac et de produits du tabac à niveaux d'alcaloïdes modifiés |
US20190271000A1 (en) | 2018-03-05 | 2019-09-05 | Altria Client Services Llc | Compositions and Methods for Producing Tobacco Plants and Products Having Altered Alkaloid Levels with Desirable Leaf Quality |
US20200029522A1 (en) | 2018-07-26 | 2020-01-30 | Altria Client Services Llc | Compositions and Methods Based on PMT Engineering for Producing Tobacco Plants and Products Having Altered Alkaloid Levels |
-
2023
- 2023-05-22 WO PCT/US2023/067281 patent/WO2023230433A1/fr unknown
Patent Citations (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4528993A (en) | 1982-08-20 | 1985-07-16 | R. J. Reynolds Tobacco Company | Process for producing moist snuff |
US4660577A (en) | 1982-08-20 | 1987-04-28 | R.J. Reynolds Tobacco Company | Dry pre-mix for moist snuff |
US4516590A (en) | 1982-11-26 | 1985-05-14 | Philip Morris Incorporated | Air-cured bright tobacco filler, blends and smoking articles |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5188958A (en) | 1986-05-29 | 1993-02-23 | Calgene, Inc. | Transformation and foreign gene expression in brassica species |
US5463174A (en) | 1986-05-29 | 1995-10-31 | Calgene Inc. | Transformation and foreign gene expression in Brassica species |
US5750871A (en) | 1986-05-29 | 1998-05-12 | Calgene, Inc. | Transformation and foreign gene expression in Brassica species |
US5159135B1 (en) | 1986-12-03 | 2000-10-24 | Agracetus | Genetic engineering of cotton plants and lines |
US5159135A (en) | 1986-12-03 | 1992-10-27 | Agracetus | Genetic engineering of cotton plants and lines |
US4848373A (en) | 1987-04-13 | 1989-07-18 | Helme Tobacco Company | Nicotine removal process and product produced thereby |
US4987907A (en) | 1988-06-29 | 1991-01-29 | Helme Tobacco Company | Chewing tobacco composition and process for producing same |
US5824877A (en) | 1988-07-22 | 1998-10-20 | Monsanto Company | Method for soybean transformation and regeneration |
US5538880A (en) | 1990-01-22 | 1996-07-23 | Dekalb Genetics Corporation | Method for preparing fertile transgenic corn plants |
US6160208A (en) | 1990-01-22 | 2000-12-12 | Dekalb Genetics Corp. | Fertile transgenic corn plants |
US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
US6399861B1 (en) | 1990-04-17 | 2002-06-04 | Dekalb Genetics Corp. | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
WO1991016024A1 (fr) | 1990-04-19 | 1991-10-31 | Vical, Inc. | Lipides cationiques servant a l'apport intracellulaire de molecules biologiquement actives |
WO1991017424A1 (fr) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Acheminement intracellulaire de substances biologiquement actives effectue a l'aide de complexes de lipides s'auto-assemblant |
US5372149A (en) | 1992-03-25 | 1994-12-13 | Roth; David S. | Sterilization process in the manufacturing of snuff |
US5591616A (en) | 1992-07-07 | 1997-01-07 | Japan Tobacco, Inc. | Method for transforming monocotyledons |
US6153812A (en) | 1994-10-26 | 2000-11-28 | Monsanto Company | Rapid and efficient regeneration of transgenic wheat plants |
US6384301B1 (en) | 1999-01-14 | 2002-05-07 | Monsanto Technology Llc | Soybean agrobacterium transformation method |
US6194636B1 (en) | 1999-05-14 | 2001-02-27 | Dekalb Genetics Corp. | Maize RS324 promoter and methods for use thereof |
US6232526B1 (en) | 1999-05-14 | 2001-05-15 | Dekalb Genetics Corp. | Maize A3 promoter and methods for use thereof |
US20040216189A1 (en) | 2001-01-09 | 2004-10-28 | Nancy Houmard | Maize chloroplast aldolase promoter compositions and methods for use thereof |
WO2004041006A1 (fr) | 2002-10-31 | 2004-05-21 | R.J. Reynolds Tobacco Company | Melanges de tabacs comprenant des tabacs orientaux |
US20060191548A1 (en) | 2003-11-07 | 2006-08-31 | Strickland James A | Tobacco compositions |
US20050178398A1 (en) | 2003-12-22 | 2005-08-18 | U.S. Smokeless Tobacco Company | Conditioning process for tobacco and/or snuff compositions |
US20060200878A1 (en) | 2004-12-21 | 2006-09-07 | Linda Lutfiyya | Recombinant DNA constructs and methods for controlling gene expression |
US9187759B2 (en) | 2005-02-23 | 2015-11-17 | North Carolina State University | Alteration of tobacco alkaloid content through modification of specific cytochrome P450 genes |
US8319011B2 (en) | 2006-12-15 | 2012-11-27 | U.S. Smokeless Tobacco Company Llc | Tobacco plants having reduced nicotine demethylase activity |
US9228195B2 (en) | 2007-11-12 | 2016-01-05 | North Carolina State University | Alteration of tobacco alkaloid content through modification of specific cytochrome P450 genes |
US8124851B2 (en) | 2007-11-12 | 2012-02-28 | North Carolina State University | Alteration of tobacco alkaloid content through modification of specific cytochrome P450 genes |
US9228194B2 (en) | 2007-11-12 | 2016-01-05 | North Carolina State University | Alteration of tobacco alkaloid content through modification of specific cytochrome P450 genes |
WO2011027315A1 (fr) | 2009-09-04 | 2011-03-10 | Moshe Danny S | Classement de produits agricoles par analyse et imagerie hyperspectrales |
US9247706B2 (en) | 2010-01-15 | 2016-02-02 | North Carolina State University | Compositions and methods for minimizing nornicotine synthesis in tobacco |
WO2018067985A1 (fr) | 2016-10-07 | 2018-04-12 | Altria Client Services Llc | Compositions et procédés de production de plants de tabac et de produits ayant une teneur réduite en nitrosamines spécifiques du tabac |
US20180119163A1 (en) | 2016-10-07 | 2018-05-03 | Altria Client Services Llc | Composition and Methods for Producing Tobacco Plants and Products Having Reduced Tobacco-Specific Nitrosamines (TSNAs) |
WO2018222667A1 (fr) * | 2017-05-31 | 2018-12-06 | 22Nd Century Limited, Llc | Procédés d'édition génomique pour produire des produits de tabac à faible teneur en nicotine |
WO2018237107A1 (fr) | 2017-06-23 | 2018-12-27 | University Of Kentucky Research Foundation | Procédé |
WO2019140297A1 (fr) | 2018-01-12 | 2019-07-18 | Altria Client Services Llc | Compositions et procédés de production de plants de tabac et de produits du tabac à niveaux d'alcaloïdes modifiés |
US20190271000A1 (en) | 2018-03-05 | 2019-09-05 | Altria Client Services Llc | Compositions and Methods for Producing Tobacco Plants and Products Having Altered Alkaloid Levels with Desirable Leaf Quality |
US20200029522A1 (en) | 2018-07-26 | 2020-01-30 | Altria Client Services Llc | Compositions and Methods Based on PMT Engineering for Producing Tobacco Plants and Products Having Altered Alkaloid Levels |
Non-Patent Citations (53)
Title |
---|
"Chemistry and Technology", 1999, BLACKWELL PUBLISHING, article "Chapters 4B and 4C of Tobacco, Production", pages: 70 - 103 |
"Compendium of Transgenic Crop Plants", 2009, BLACKWELL PUBLISHING |
"CORESTA Method", DETERMINATION OF NICOTINE IN TOBACCO AND TOBACCO PRODUCTS BY GAS CHROMATOGRAPHIC ANALYSIS, February 2005 (2005-02-01), pages 62 |
"Oxford Dictionary of Biology", 2008, OXFORD UNIVERSITY PRESS |
"PCR Primer: A Laboratory Manual", 1995, COLD SPRING HARBOR LABORATORY PRESS |
"Protocol for Analysis of Nicotine, Total Moisture and pH in Smokeless Tobacco Products", vol. 64, 23 March 1999, FEDERAL REGISTER, article "Centers for Disease Control and Prevention's" |
"The Handbook of Plant Metabolomics", 28 May 2013, WILEY-BLACKWELL |
"The UniProt Consortium", NUCLEIC ACIDS RESEARCH, vol. 47, 2019, pages D506 - 515 |
ADV. APPL. MATH., vol. 2, 1981, pages 482 - 489 |
AGRAWAL ET AL., MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, vol. 67, 2003, pages 657 - 685 |
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410 |
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402 |
ALTSCHUL ET AL.: "Basic local alignment search tool", J. MOL. BIOL., vol. 215, 1990, pages 403 - 410, XP002949123, DOI: 10.1006/jmbi.1990.9999 |
ANZALONE ET AL., NATURE, vol. 576, 2019, pages 149 - 157 |
BOWMAN ET AL., TOBACCO SCIENCE, vol. 32, 1988, pages 39 - 40 |
BURLEYDARK: "Tobacco Production Guide", December 2018, UNIVERSITY OF KENTUCKY, THE UNIVERSITY OF TENNESSEE |
CHENNA ET AL.: "Multiple sequence alignment with the Clustal series of programs", NUCLEIC ACIDS RESEARCH, vol. 31, 2003, pages 3497 - 3500, XP002316493, DOI: 10.1093/nar/gkg500 |
COLLINS ET AL., TOBACCO SCIENCE, vol. 13, 1969, pages 79 - 81 |
DAVIS, TOBACCO SCIENCE, vol. 20, 1976, pages 139 - 144 |
DEWEYXIE: "Molecular genetics of alkaloid biosynthesis in Nicotiana tabacum", PHYTOCHEMISTRY, vol. 94, 2013, pages 10 - 27, XP055193990, DOI: 10.1016/j.phytochem.2013.06.002 |
FACCHINI P J ET AL: "Plant aromatic L-amino acid decarboxylases: evolution, biochemistry, regulation, and metabolic engineering applications", PHYTOCHEMISTRY, ELSEVIER, AMSTERDAM , NL, vol. 54, no. 2, 1 May 2000 (2000-05-01), pages 121 - 138, XP027253886, ISSN: 0031-9422, [retrieved on 20000501] * |
GAUDELLI ET AL., NATURE, vol. 551, 2017, pages 464 - 471 |
GOLDMAN ET AL., EMBO JOURNAL, vol. 13, 1994, pages 2976 - 2984 |
GRIFFITHS-JONES ET AL., NUCLEIC ACIDS RES., vol. 31, 2003, pages 439 - 441 |
GUILLET G ET AL: "Expression of tryptophan decarboxylase and tyrosine decarboxylase genes in tobacco results in altered biochemical and physiological phenotypes", PLANT PHYSIOLOGY, AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, USA, vol. 122, no. 3, 1 March 2000 (2000-03-01), pages 933 - 943, XP002506682, ISSN: 0032-0889 * |
HEIDI L. DALTON ET AL: "Effects of down-regulating ornithine decarboxylase upon putrescine-associated metabolism and growth in Nicotiana tabacum L.", JOURNAL OF EXPERIMENTAL BOTANY, vol. 67, no. 11, 28 April 2016 (2016-04-28), GB, pages 3367 - 3381, XP055583634, ISSN: 0022-0957, DOI: 10.1093/jxb/erw166 * |
HIBI ET AL., PLANT PHYSIOLOGY, vol. 100, 1992, pages 826 - 35 |
HIDALGO ET AL., SCIENTIFIC REPORTS, vol. 7, 2017, pages 17976 |
HIDALGO MARTINEZ DIEGO ET AL: "Genetic attenuation of alkaloids and nicotine content in tobacco ()", PLANTA, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 251, no. 4, 3 April 2020 (2020-04-03), XP037090312, ISSN: 0032-0935, [retrieved on 20200403], DOI: 10.1007/S00425-020-03387-1 * |
HORSCH ET AL., SCIENCE, vol. 227, 1985, pages 1229 - 1231 |
KAJIKAWA ET AL., PLANT PHYSIOL., vol. 174, 2017, pages 999 - 1011 |
KATOHSUZUKI, NUCLEIC ACIDS RES., 2007 |
KHVOROVA ET AL., CELL, vol. 115, 2003, pages 209 - 216 |
KIM, NATURE REV. MOL. CELL. BIOL., vol. 6, 2005, pages 376 - 385 |
KOMOR ET AL., NATURE, vol. 533, 2016, pages 420 - 424 |
LARKIN MA ET AL.: "Clustal W and Clustal X version 2.0", BIOINFORMATICS, vol. 23, 2007, pages 2947 - 48 |
LIU ET AL., PLANT CELL, vol. 26, 2014, pages 741 - 753 |
LIVAKSCHMITTGEN, METHODS, vol. 25, 2001, pages 402 - 408 |
MAYO ET AL., NAT PROTOC, vol. 1, 2006, pages 1105 - 11 |
MILLER ET AL., TOBACCO INTERN., vol. 192, 1990, pages 55 - 57 |
MIZUSAKI ET AL., PLANT AND CELL PHYSIOLOGY, vol. 14, 1973, pages 103 - 110 |
MOLLA ET AL., NATURE PLANTS, vol. 7, 2021, pages 1166 - 1187 |
REYNOLDS ET AL., NATURE BIOTECHNOL., vol. 22, 2004, pages 326 - 330 |
SEELYPEGG, J. BIOL. CHEM., vol. 258, 1983, pages 2496 - 2500 |
SHOJI ET AL., PLANT CELL, no. 10, 2010, pages 3390 - 409 |
THOMPSON ET AL.: "Clustal W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice", NUCLEIC ACIDS RESEARCH, vol. 22, 1994, pages 4673 - 4680, XP002956304 |
TSO: "Tobacco, Production, Chemistry and Technology", 1999, BLACKWELL PUBLISHING |
WANG ET AL., CURR. OPIN. PLANT BIOL., vol. 27, 2015, pages 118 - 124 |
WERNSMAN, E. A.RUFTY, R. C.: "Cultivar Development. Crop Species", 1987, MACMILLAN PUBLISHING GO., INC., article "Tobacco", pages: 669 - 698 |
YU ET AL., ENZYME MICROB. TECHNOL., vol. 49, 2011, pages 272 - 276 |
ZENG ET AL., MOL. CELL, vol. 9, 2002, pages 1327 - 1333 |
ZHANGMADDEN, GENOME RES., vol. 7, 1997, pages 649 - 656 |
ZHOU ET AL., APPL. MICROBIOL BIOTECHNOL., vol. 90, 2011, pages 1229 - 1239 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108271341B (zh) | 用于生产烟草植物的组合物和方法以及具有改变的生物碱含量的制品 | |
US11602118B2 (en) | Methods and compositions related to improved nitrogen utilization efficiency in tobacco | |
CN111836539A (zh) | 用于产生烟草植物和具有经过改变的生物碱水平的产品的组合物和方法 | |
US20240218386A1 (en) | Compositions and Methods for Producing Tobacco Plants and Products Having Altered Alkaloid Levels | |
US12077765B2 (en) | Tobacco plants comprising reduced nicotine and reduced tobacco specific nitrosamines | |
EP4161255A1 (fr) | Compositions et procédés de production de plants de tabac et de produits aux niveaux d'alcaloïdes modifiés | |
US20240067979A1 (en) | Pale yellow locus and its applications in tobacco | |
US20240067977A1 (en) | Compositions and methods for producing tobacco plants and products having altered alkaloid levels with desirable leaf quality via manipulating leaf quality genes | |
US20230145103A1 (en) | Compositions and methods for producing tobacco plants and products having reduced or eliminated suckers | |
WO2018119124A1 (fr) | Compositions et procédés de production de tabac et de produits à taux d'alcaloïdes modifiés | |
US20240229054A9 (en) | Methods and compositions for regulating alkaloids in tobacco | |
WO2023230433A1 (fr) | Procédés et compositions pour la régulation des alcaloïdes dans le domaine du tabac | |
US20210230627A1 (en) | Methods and compositions related to improved nitrogen use efficiency |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23733821 Country of ref document: EP Kind code of ref document: A1 |